WO2022058902A1 - Compounds and compositions as sppl2a inhibitors - Google Patents

Compounds and compositions as sppl2a inhibitors Download PDF

Info

Publication number
WO2022058902A1
WO2022058902A1 PCT/IB2021/058398 IB2021058398W WO2022058902A1 WO 2022058902 A1 WO2022058902 A1 WO 2022058902A1 IB 2021058398 W IB2021058398 W IB 2021058398W WO 2022058902 A1 WO2022058902 A1 WO 2022058902A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
benzo
oxo
pyrazolo
diazepin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2021/058398
Other languages
English (en)
French (fr)
Inventor
Trixi Brandl
Claus Ehrhardt
Robert Epple
Christian Markert
Pascal Rigollier
Juraj Velcicky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA3192763A priority Critical patent/CA3192763A1/en
Priority to FIEP21773886.3T priority patent/FI4214210T3/fi
Priority to AU2021342783A priority patent/AU2021342783A1/en
Priority to EP21773886.3A priority patent/EP4214210B1/en
Priority to JP2023517751A priority patent/JP7771172B2/ja
Priority to SI202130298T priority patent/SI4214210T1/sl
Priority to LTEPPCT/IB2021/058398T priority patent/LT4214210T/lt
Priority to CR20230142A priority patent/CR20230142A/es
Priority to MX2023003122A priority patent/MX2023003122A/es
Priority to MA61557A priority patent/MA61557B1/fr
Priority to US18/044,455 priority patent/US20230365571A1/en
Priority to CN202180074962.XA priority patent/CN116615425B/zh
Priority to SM20250216T priority patent/SMT202500216T1/it
Priority to PL21773886.3T priority patent/PL4214210T3/pl
Priority to RS20250568A priority patent/RS66874B1/sr
Application filed by Novartis AG filed Critical Novartis AG
Priority to HRP20250562TT priority patent/HRP20250562T1/hr
Priority to DK21773886.3T priority patent/DK4214210T3/da
Priority to PE2023001167A priority patent/PE20231099A1/es
Priority to IL300953A priority patent/IL300953B1/en
Priority to MDE20230725T priority patent/MD4214210T2/ro
Priority to EP25163259.2A priority patent/EP4578451A3/en
Priority to KR1020237011546A priority patent/KR20230069947A/ko
Priority to ES21773886T priority patent/ES3028668T3/es
Publication of WO2022058902A1 publication Critical patent/WO2022058902A1/en
Priority to JOJO/P/2023/0044A priority patent/JOP20230044A1/ar
Priority to DO2023000055A priority patent/DOP2023000055A/es
Anticipated expiration legal-status Critical
Priority to CONC2023/0004646A priority patent/CO2023004646A2/es
Priority to JP2025186205A priority patent/JP2026041723A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to tricyclic compounds comprising a diazepinone moiety which are effective in inhibiting signal peptide peptidase like protease 2a (Sppl2a), to pharmaceutical compositions containing such inhibitors, to a method for synthesizing said novel derivatives and to methods of using such inhibitors and compositions.
  • Sppl2a signal peptide peptidase like protease 2a
  • the protein Sppl2a appears to play a role in innate and adaptive immunity by cleaving different transmembrane anchored proteins and thereby affecting the function of a varity of immune cells.
  • Sppl2a was initially described as the protease cleaving the membrane spanning portion of TNF- ⁇ and thereby controlling the release of IL-12 from dendritic cells. Recent observations suggest that Sppl2a might be implicated in the processing of CD74, also known as the invariant chain, an important mediator of antigen presentation via class II molecules, which allows differentiation of foreign antigens from self antigens. Many autoimmune diseases may evolve when the immune system loses its capacity to discriminate “self” from “non-self”. A recent publication from D. Beisner et al. “The intramembrane protease Sppl2a is required for B cell and DC development and survival via cleavage of the invariant chain”, J. Exp.
  • CD74 is cleaved by Sppl2a. Inhibition of this process in mice may result in a significant reduction of the number of mature B cells and myeloid dendritic cells.
  • the scientific literature further suggests that inhibiting Sppl2a leads to the accumulation of the N-terminal fragment of CD74 (p8) in intracellular compartments, thereby inducing the death of B cells and myeloid dendritic cells.
  • the molecular details of Sppl2a processing and disappearance of B cells/ myeloid dendritic cells are still poorly understood, the accumulation of the umprocessed CD74 appears to impair T cell dependent antibody response in mice.
  • the serpentine line in a compound of formula (I) characterizing the chemical bond leading to substituent R 4 indicates two (2) stereochemical options.
  • the stereochemistry of the carbon atom to which R 4 is being attached is (S), in another embodiment said stereochemistry is (R), or in still another embodiment it is a mixture thereof.
  • the serpentine line in a compound of formula (I) characterizing the chemical bond leading to substituent R 3 indicates two (2) stereochemical options.
  • the stereochemistry of the carbon atom to which R 3 is being attached is (S), in another embodiment said stereochemistry is (R), or in still another embodiment it is a mixture thereof.
  • Another aspect of the present invention is a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
  • Another aspect of the present invention is a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt, and one or more pharmaceutically acceptable carriers.
  • the invention provides a method of treating or preventing a disease or disorder mediated by the activity of signal peptide peptidase like protease 2a (Sppl2a), wherein the method comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt.
  • the invention provides a method of treating or preventing a disease or disorder mediated by the activity of signal peptide peptidase like protease 2a (Sppl2a), wherein the method comprises administering to a subject in need of such treatment a compound of the invention, or a pharmaceutically acceptable salt.
  • the invention provides a method of treating an autoimmune disease in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
  • the invention provides a method of treating an autoimmune disease in a subject in need thereof, wherein the method comprises administering to the subject a compound of the invention, or a pharmaceutically acceptable salt thereof.
  • the invention provides a method of treating an autoimmune disease in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, and wherein the autoimmune disease is Sjoegren’s disease, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), lupus nephritis, systemic sclerosis, multiple sclerosis (MS), autoimmune hepatitis, uveitis, pemphigus vulgaris, pemphigus foliaceus,myasthenia gravis, Hashimoto thyroiditis, thrombocytopenia purpura, myocarditis, atopic dermatitis, Goodpasture syndrome or type I diabetes.
  • SLE systemic lupus erythematosus
  • RA rheumatoid arthritis
  • MS multiple sclerosis
  • autoimmune hepatitis uveitis
  • the invention provides a method of treating an autoimmune disease in a subject in need thereof, wherein the method comprises administering to the subject a compound of the invention, or a pharmaceutically acceptable salt thereof, and wherein the autoimmune disease is Sjoegren’s disease, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), lupus nephritis, systemic sclerosis, multiple sclerosis (MS), autoimmune hepatitis, uveitis, pemphigus vulgaris, pemphigus foliaceus,myasthenia gravis, Hashimoto thyroiditis, thrombocytopenia purpura, myocarditis, atopic dermatitis, Goodpasture syndrome, or type I diabetes.
  • Sjoegren’s disease systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), lupus nephritis, systemic sclerosis, multiple
  • the invention provides a method of treating graft versus host disease (GvHD) in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
  • the graft versus host disease (GvHD) is an acute graft versus host disease, while in other embodiments the graft versus host disease (GvHD) is a chronic graft versus host disease.
  • the invention provides a method of preventing graft versus host disease (GvHD) in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, prior to transplantation.
  • the graft versus host disease is an acute graft versus host disease, while in other embodiments the graft versus host disease (GvHD) is a chronic graft versus host disease.
  • the invention provides a method of treating graft versus host disease (GvHD) in a subject, wherein the method comprises administering to the subject a compound of the invention, or a pharmaceutically acceptable salt thereof.
  • the graft versus host disease is an acute graft versus host disease, while in other embodiments the graft versus host disease (GvHD) is a chronic graft versus host disease.
  • the invention provides a method of preventing graft versus host disease (GvHD) in a subject, wherein the method comprises administering to the subject a compound of the invention, or a pharmaceutically acceptable salt thereof, prior to transplantation.
  • the graft versus host disease is an acute graft versus host disease
  • the graft versus host disease is a chronic graft versus host disease.
  • the invention provides use of a compound of of the invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or disorder associated with or mediated by the activity of signal peptide peptidase like protease 2a (Sppl2a).
  • the invention provides use of a compound of the invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of an autoimmune disease.
  • the invention provides use of a compound of the invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of an autoimmune disease, wherein the autoimmune disease is Sjoegren’s disease, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), lupus nephritis, systemic sclerosis, multiple sclerosis (MS), autoimmune hepatitis, uveitis, pemphigus vulgaris, pemphigus foliaceus,myasthenia gravis, Hashimoto thyroiditis, thrombocytopenia purpura, myocarditis, atopic dermatitis, Goodpasture syndrome, or type I diabetes.
  • Sjoegren’s disease systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), lupus nephritis, systemic sclerosis, multiple sclerosis (MS), autoimmune he
  • the invention provides use of a compound of the invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of a graft versus host disease (GvHD).
  • the graft versus host disease is an acute graft versus host disease
  • the graft versus host disease is a chronic graft versus host disease.
  • the invention provides the use of a compound of the invention, or a pharmaceutically acceptable salt thereof, in the treatment of a disease or disorder associated with or mediated by the activity of signal peptide peptidase like protease 2a (Sppl2a).
  • the invention provides the use of a compound of the invention, or a pharmaceutically acceptable salt thereof, in the treatment of an autoimmune disease.
  • the invention provides the use of a compound of the invention, or a pharmaceutically acceptable salt thereof, in the treatment of an autoimmune disease, wherein the autoimmune disease is Sjoegren’s disease, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), lupus nephritis, systemic sclerosis, multiple sclerosis (MS), autoimmune hepatitis, uveitis, pemphigus vulgaris, pemphigus foliaceus,myasthenia gravis, Hashimoto thyroiditis, thrombocytopenia purpura, myocarditis, atopic dermatitis, Goodpasture syndrome, or type I diabetes.
  • Sjoegren’s disease systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), l
  • the invention provides the use of a compound of the invention, or a pharmaceutically acceptable salt thereof, in the treatment or prevention of a graft versus host disease (GvHD).
  • the graft versus host disease is an acute graft versus host disease, while in other embodiments the graft versus host disease (GvHD) is a chronic graft versus host disease.
  • the invention provides a compound of the invention, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease or disorder associated with of mediated by the activity of signal peptide peptidase like protease 2a (Sppl2a).
  • the invention provides a compound of the invention, or a pharmaceutically acceptable salt thereof, for use in the treatment of an autoimmune disease.
  • the invention provides a compound of the invention, or a pharmaceutically acceptable salt thereof, for use in the treatment of an autoimmune disease,wherein the autoimmune disease is Sjoegren’s disease, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), lupus nephritis, systemic sclerosis, multiple sclerosis (MS), autoimmune hepatitis, uveitis, pemphigus vulgaris, pemphigus foliaceus,myasthenia gravis, Hashimoto thyroiditis, thrombocytopenia purpura, myocarditis, atopic dermatitis, Goodpasture syndrome, or type I diabetes.
  • Sjoegren’s disease systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), lupus
  • the invention provides a compound of the invention, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a graft versus host disease (GvHD).
  • the graft versus host disease (GvHD) is an acute graft versus host disease, while in other embodiments the graft versus host disease (GvHD) is a chronic graft versus host disease.
  • alkyl refers to a fully saturated branched or straight chain hydrocarbon having up to 20 carbon atoms.
  • an alkyl group is a "C 1 - C 2 alkyl", “C 1 -C 3 alkyl", “C 1 -C 4 alkyl", “C 1 -C 5 alkyl", “C 1 -C 6 alkyl”, “C 1 -C 7 alkyl”, “C 1 -C 8 alkyl”, “C 1 - C 9 alkyl” or “C 1 -C 10 alkyl”, wherein the terms “C 1 -C 2 alkyl", “C 1 -C 3 alkyl”, “C 1 -C 4 alkyl", “C 1 -C 5 alkyl", “C 1 -C 6 alkyl”, “C 1 -C 7 alkyl", “C 1 -C 8 alkyl", “C 1 -C 9 alkyl” and “C 1 -C 10 alkyl”, as used herein, refer to an alkyl group containing at least 1, and at most 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, respectively.
  • Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n- butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2- dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl and n-decyl.
  • alkoxy refers to -O-alkyl or-alkyl-O-, wherein “alkyl” is as defined herein.
  • an alkoxy group is a "C 1 -C 2 alkoxy", “C 1 -C 3 alkoxy", “C 1 - C 4 alkoxy”, “C 1 -C 5 alkoxy", “C 1 -C 6 alkoxy”, “C 1 -C 7 alkoxy", “C 1 -C 8 alkoxy", "C 1 -C 9 alkoxy” or "C 1 - C 10 alkoxy", wherein the terms "C 1 -C 3 alkoxy", “C 1 -C 4 alkoxy”, “C 1 -C 5 alkoxy", “C 1 -C 6 alkoxy”, “C 1 - C 7 alkoxy", “C 1 -C 8 alkoxy", “C 1 -C 9 alkoxy” and "C 1 -C 10 alkoxy”, as used herein refer to
  • alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n- pentoxy, isopentoxy, hexoxy, heptoxy, octoxy, nonoxy and decoxy.
  • C 3 -C 8 cycloalkyl refers to a fully saturated, monocyclic hydrocarbon ring system having 3 to 8 carbon atoms as ring members.
  • Non-limiting examples of such “C 3 -C 8 cycloalkyl” groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • the term “C 3 -C 6 cycloalkyl” as used herein refers to a fully saturated, monocyclic hydrocarbon ring system having 3 to 6 carbon atoms as ring members.
  • Non-limiting examples of such “C 3 -C 8 cycloalkyl” groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • 3 to 6 membered carbocyclic ring refers to a 3 to 6 membered, saturated or partially saturated hydrocarbon ring.
  • carbocyclic ring groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.
  • C 3 -C 6 cycloalkenyl refers to a partially saturated (but not aromatic), monocyclic hydrocarbon ring system having 3 to 6 carbon atoms as ring members.
  • C 1 -C 6 alkyl-phenyl refer to a C 1 -C 6 alkyl as defined above which is substituted with a phenyl group.
  • Non-limiting example of a C 1 -C 6 alkyl-phenyl is benzyl.
  • haloalkyl refers to an alkyl group as defined herein, wherein at least one of the hydrogen atoms of the alkyl is replaced by a halo group (as defined herein).
  • the haloalkyl can be monohaloalkyl, dihaloalkyl, trihaloalkyl, or polyhaloalkyl including perhaloalkyl.
  • a monohaloalkyl can have one iodo, bromo, chloro or fluoro within the alkyl group.
  • Dihaloalkyl and polyhaloalkyl groups can have two or more of the same halo atoms or a combination of different halo groups within the alkyl.
  • the polyhaloalkyl typically contains up to 6, or 4, or 3, or 2 halo groups.
  • Non-limiting examples of haloalkyl include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.
  • a perhalo-alkyl refers to an alkyl having all hydrogen atoms replaced with halo atoms, e.g., trifluoromethyl.
  • haloalkyl groups include monofluoro-, difluoro- and trifluoro- substituted methyl and ethyl groups, e.g. CF 3 , CHF 2 , CH 2 F, CH 2 CHF 2 and CH 2 CF 3 .
  • C 1 -C 6 haloalkyl refers to the respective "C 1 -C 6 alkyl", as defined herein, wherein at least one of the hydrogen atoms of the "C 1 -C 6 alkyl" is replaced by a halo group (as defined herein).
  • the C 1 -C 6 haloalkyl groups can be monoC 1 -C 6 haloalkyl, wherein such C 1 -C 6 haloalkyl groups have one iodo, one bromo, one chloro or one fluoro. Additionally, the C 1 - C 6 haloalkyl groups can be diC 1 -C 6 haloalkyl wherein such C 1 -C 6 haloalkyl groups can have two halo atoms independently selected from iodo, bromo, chloro or fluoro.
  • the C 1 - C 6 haloalkyl groups can be polyC 1 -C 6 haloalkyl wherein such C 1 -C 6 haloalkyl groups can have two or more of the same halo atoms or a combination of two or more different halo atoms.
  • Such polyC 1 -C 6 haloalkyl can be perhaloC 1 -C 6 haloalkyl where all the hydrogen atoms of the respective C 1 -C 6 alkyl have been replaced with halo atoms and the halo atoms can be the same or a combination of different halo atoms.
  • C 1 -C 6 haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.
  • haloalkoxy refers to the group –O-haloalkyl wherein at least one of the hydrogen atoms of the alkyl group of the alkoxy is replaced by a halo group (as defined herein).
  • the haloalkoxy can be monohaloalkoxy, dihaloalkoxy, trihaloalkoxy, or polyhaloalkoxy including perhaloalkoxy.
  • a monohaloalkoxy can have one iodo, bromo, chloro or fluoro within the alkyl group.
  • Dihaloalkoxy and polyhaloalkoxy groups can have two or more of the same halo atoms or a combination of different halo groups within the alkyl.
  • the polyhaloalkoxy contains up to 6, or 4, or 3, or 2 halo groups.
  • haloalkoxy include fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, pentafluoroethoxy, heptafluoropropoxy, difluorochloromethoxy, dichlorofluoromethoxy, difluoroethoxy, difluoropropoxy, dichloroethoxy and dichloropropoxy.
  • a perhalo-alkoxy refers to an alkoxy having all hydrogen atoms replaced with halo atoms, e.g., trifluoromethoxy.
  • haloalkoxy groups include monofluoro-, difluoro- and trifluoro- substituted methoxy and ethoxygroups, e.g. -OCF 3 , -OCHF 2 , -OCH 2 F, -OCH 2 CHF 2 and -OCH 2 CF 3 .
  • C 1 -C 6 haloalkoxy refers to the group –O-C 1 -C 6 haloalkyl, wherein at least one of the hydrogen atoms of the "C 1 -C 6 alkyl" of the "C 1 -C 6 alkoxy" is replaced by a halo group (as defined herein).
  • the C 1 -C 6 haloalkoxy groups can be monoC 1 -C 6 haloalkoxy, wherein such C 1 -C 6 haloalkoxy groups have one iodo, one bromo, one chloro or one fluoro. Additionally, the C 1 -C 6 haloalkoxy groups can be diC 1 -C 6 haloalkoxy wherein such C 1 - C 6 haloalkoxy groups can have two halo atoms independently selected from iodo, bromo, chloro or fluoro.
  • the C 1 -C 6 haloalkoxy groups can be polyC 1 -C 6 haloalkoxy wherein such C 1 -C 6 haloalkoxy groups can have two or more of the same halo atoms or a combination of two or more different halo atoms.
  • Such polyC 1 -C 6 haloalkoxy can be perhaloC 1 -C 6 haloalkoxy where all the hydrogen atoms of the respective C 1 -C 6 alkoxy have been replaced with halo atoms and the halo atoms can be the same or a combination of different halo atoms.
  • Non-limiting examples of "C 1 -C 6 haloalkoxy” groups include fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, pentafluoroethoxy, heptafluoropropoxy, difluorochloromethoxy, dichlorofluoromethoxy, fluoroethoxy, difluoroethoxy, trifluoroethoxy, difluoropropoxy, dichloroethoxy and dichloropropoxy.
  • halogen or “halo” as used herein, refer to fluoro (F), chloro (Cl), bromo (Br) and iodo (I).
  • heteroatoms refers to nitrogen (N), oxygen (O) or sulfur (S) atoms.
  • heteroaryl refers to an aromatic ring system containing one or more heteroatoms. Heteroaryl groups containing more than one heteroatom may contain different heteroatoms. Heteroaryl groups may be monocyclic ring systems or fused bicyclic ring systems. Monocyclic heteroaryl rings have from 5 to 6 ring atoms. Bicyclic heteroaryl rings have from 7 to 12 ring member atoms. Bicyclic heteroaryl rings include those ring systems wherein a heteroaryl ring is fused to a phenyl ring.
  • heteroaryl groups include benzofuranyl, benzo[c]thiophenyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, cinnolinyl, furazanyl, furyl, imidazolyl, indolyl, indolizinyl, indazolyl, isoindolyl, isoquinolinyl, isoxazolyl, isothiazolyl, oxazolyl, oxaindolyl, oxadiazolyl (including 1,3,4-oxadiazolyl and 1,2,4-oxadiazolyl), purinyl, pyrazolyl, pyrrolyl, phthalazinyl, pyridinyl (including 2-, 3-, and 4-pyridinyl), pyridazinyl, pyrazinyl, pyrimidinyl, quinoxaliny
  • 5-membered heteroaryl refers to an aromatic, 5 membered monocyclic ring system having 1, 2 or 3 heteroatoms as ring members, each of which is independently selected from N, O and S.
  • Non-limiting examples of such 5 membered heteroaryl groups, as used herein, include furyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, pyrrolyl, pyrazolyl, thiadiazolyl, thiazolyl, thienyl and triazolyl.
  • the "5-membered heteroaryl”, as used herein, refers to an aromatic, 5 membered monocyclic ring system having 1 or 2 heteroatoms as ring members, each of which is independently selected from N, O and S.
  • Non-limiting examples of such 5 membered heteroaryl groups, as used herein, include furyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, pyrrolyl, pyrazolyl, thiadiazolyl, thiazolyl, thienyl and triazolyl.
  • 6-membered heteroaryl refers to an aromatic, 6 membered monocyclic ring system having 1, 2 or 3 heteroatoms as ring members, each of which is independently selected from N, O and S.
  • Non-limiting examples of such 6 membered heteroaryl groups, as used herein, include pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl and triazinyl.
  • 6-membered heteroaryl refers to an aromatic, 6 membered monocyclic ring system having 1 or 2 heteroatoms as ring members, each of which is independently selected from N, O and S.
  • Non-limiting examples of such 6 membered heteroaryl groups include pyridyl, pyridazinyl, pyrazinyl, and pyrimidinyl.
  • Non-limiting examples of such bicyclic heteroaryl groups include indolyl, quinolinyl, isoquinolinyl, indazolyl, purinyl, phthalazinyl, naphthyridinyl, quinazolinyl, cinnolinyl, thieno[2,3-b]furanyl, 1H- pyrazolo[4,3-d]-oxazolyl, imidazo[2,1-b] thiazolyl, pyrazino[2,3-d]pyridazinyl, imidazo[1,2- b][1,2,4]triazinyl, benzoxazolyl, benzimidazolyl, imidazopyridinyl and benzothiazolyl.
  • such a bicyclic heteroaryl group is 1H-benzo[d]imidazolyl or 1H-imidazo[4,5- c]pyridinyl.
  • 4-6 membered heterocyclyl refers to 4 to 6 membered, saturated or partially saturated hydrocarbon ring containing 1 to 2 heteroatoms as ring members, each independently selected from N, NH, NR A , O or S, where R A is H, C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl.
  • the heterocyclyl group can be attached to another group at a nitrogen or a carbon atom.
  • Non- limiting examples of 4-6 membered heterocycloalkyl groups include azetadinyl, azetadin-1-yl, azetadin-2-yl, azetadin-3-yl, oxetanyl, oxetan-2-yl, oxetan-3-yl, oxetan-4-yl, thietanyl, thietan-2-yl, thietan-3-yl, thietan-4-yl, pyrrolidinyl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolidin-4-yl, pyrrolidin-5-yl, tetrahydrofuranyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrofuran-4-yl, te
  • isomers refers to different compounds that have the same molecular formula but differ in arrangement and configuration of the atoms.
  • an optical isomer or “a stereoisomer” refers to any of the various stereo isomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom.
  • chiral refers to molecules which have the property of non- superimposability on their mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound.
  • Enantiomers are a pair of stereoisomers that are non- superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a "racemic” mixture. The term is used to designate a racemic mixture where appropriate.
  • “Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The absolute stereochemistry is specified according to the Cahn- lngold- Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S.
  • Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line.
  • Certain compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp.1289- 1329).
  • a therapeutically effective amount of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc.
  • a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a subject, is effective to (1) at least partially alleviating, inhibiting, preventing and/or ameliorating a condition, or a disorder or a disease (i) mediated by Sppl2a, or (ii) associated with or mediated by Sppl2a activity, or (iii) characterized by activity (normal or abnormal) of Sppl2a; or (2) reducing or inhibiting the activity of Sppl2a; or (3) reducing or inhibiting the expression of Sppl2a.
  • a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of Sppl2a; or at least partially reducing or inhibiting the expression of Sppl2a.
  • subject as used herein may refer to an animal. The animal may be a mammal. A subject also refers to for example, primates (e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate.
  • the subject is a human.
  • the terms “inhibit”, “inhibition” or “inhibiting”, as used herein, refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
  • the term “treat”, “treating” or “treatment” of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
  • “treat”, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
  • the term “preventing” refer to delaying the onset or development or progression of the disease or disorder.
  • a subject is “in need of” a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.
  • the terms “compound of the invention”, “compounds of the invention”, “compound of the present invention” or “compounds of the present invention” refers to a compound or compounds of Formula (I), Formula (II), Formula (III), Formula (IV), and subformulae thereof (such as Formula (IIA), Formula (IIB), Formula (IIC), Formula (IID), Formula (IIIA), Formula (IIIB), Formula (IIIC) and Formula (IIID)) and exemplified compounds, and salts thereof, as well as all stereoisomers (including diastereoisomers and enantiomers) thereof.
  • Various enumerated embodiments of the present invention are described herein.
  • Embodiment 4. The compound of Embodiment 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 10 is a 9 or 10 membered bicyclic heteroaryl having 1 to 4 heteroatoms as ring members each independently selected from N, O and S, wherein the bicyclic heteroaryl is unsubstituted or the bicyclic heteroaryl is substituted with one or more R 6 .
  • Embodiment 5 The compound of Embodiment 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 10 is wherein R 6 is H, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, cyano or halogen.
  • Embodiment 6. The compound of any one of Embodiments 1 to 4, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 4 is H.
  • Embodiment 7 The compound of any one of Embodiments 1 to 4, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 4 is C 1 -C 6 alkyl.
  • Embodiment 9 The compound of any one of Embodiments 1 to 4, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 4 is C 1 -C 6 alkyl-phenyl.
  • Embodiment 9 The compound of Embodiment 1, or a pharmaceutically acceptable salt or stereoisomer thereof, having a structure of Formula (II) Embodiment 10.
  • Embodiment 12 The compound of Embodiment 1, or a pharmaceutically acceptable salt or stereoisomer thereof, having a structure of Formula (IV): Embodiment 12.
  • Embodiment 13 The compound of any one of Embodiments 1 to 11, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is H.
  • Embodiment 13 The compound of any one of Embodiments 1 to 11, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is C 1 -C 6 alkyl.
  • Embodiment 14 The compound of any one of Embodiments 1 to 11, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is halogen.
  • Embodiment 15 The compound of any one of Embodiments 1 to 11, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 11 is H.
  • Embodiment 17 The compound of any one of Embodiments 1 to 11, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 11 is C 1 -C 6 alkyl.
  • Embodiment 17 The compound of any one of Embodiments 1 to 11, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 11 is halogen.
  • Embodiment 18 The compound of any one of Embodiments 1 to 11, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 and R 11 together with the carbon atom to which they are attached, form a 3 to 6 membered carbocyclic ring.
  • Embodiment 19 The compound of any one of Embodiments 1 to 11, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 and R 11 together with the carbon atom to which they are attached, form a 3 to 6 membered carbocyclic ring.
  • Embodiment 20 The compound of any one of Embodiments 1 to 19, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 and R 11 together with the carbon atom to which they are attached, form a cyclopropyl ring.
  • Embodiment 20 The compound of any one of Embodiments 1 to 19, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 is H.
  • Embodiment 21 The compound of any one of Embodiments 1 to 19, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 is halogen.
  • Embodiment 22 The compound of any one of Embodiments 1 to 19, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 is F.
  • Embodiment 23 The compound of any one of Embodiments 1 to 19, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 is F.
  • Embodiment 1 or Embodiment 9 or a pharmaceutically acceptable salt or stereoisomer thereof, having a structure of Formula (IIA), Formula (IIB), Formula (IIC) or Formula (IID): Embodiment 28.
  • Embodiment 31 The compound of Embodiment 1 or Embodiment 10, or a pharmaceutically acceptable salt or stereoisomer thereof, having a structure of Formula (IIIC): Embodiment 31.
  • Embodiment 34 The compound of any one of Embodiments 1 to 32, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is H.
  • Embodiment 35 The compound of any one of Embodiments 1 to 32, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is C 1 -C 6 alkyl.
  • Embodiment 35 The compound of any one of Embodiments 1 to 32, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is methyl, ethyl, propyl or iso-propyl.
  • Embodiment 36 The compound of any one of Embodiments 1 to 32, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is C 1 -C 6 halolkyl.
  • Embodiment 37 The compound of any one of Embodiments 1 to 32, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is C 1 -C 6 halolkyl.
  • Embodiment 38 The compound of any one of Embodiments 1 to 32, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is C 1 -C 6 alkyl-phenyl.
  • Embodiment 39 The compound of any one of Embodiments 1 to 32, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is -CH 2 -phenyl.
  • Embodiment 40 The compound of any one of Embodiments 1 to 32, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is C 3 -C 6 cycloalkyl.
  • Embodiment 41 The compound of any one of Embodiments 1 to 32, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is cyclopropyl or cyclobutyl.
  • Embodiment 42 The compound of any one of Embodiments 1 to 32, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is C 1 -C 6 alkyl substituted with C 1 - C 6 alkoxy.
  • Embodiment 43 The compound of any one of Embodiments 1 to 32, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is -CH 2 CH 2 OCH 3 .
  • Embodiment 44 The compound of any one of Embodiments 1 to 32, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is -CH 2 CH 2 OCH 3 .
  • Embodiment 46 The compounds of any one of Embodiments 1 to 43, or a pharmaceutically acceptable salt thereof, wherein R 5 is: wherein R 5a is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl or halogen; R 5b is -C(O)-NH-C 1 -C 6 alkyl, -C(O)NH-C 1 -C 6 haloalkyl, -C(O)NHphenyl, C 1 -C 6 alkoxy, C 1 - C 6 haloalkoxy, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkenyl, 4- to 6-membered heterocyclyl, 5- or 6-membered ring heteroaryl; wherein heteroaryl is optionally substituted with halogen, C 1 -C 6 alkyl, C 1 -C 6 haloakyl, C 1 -C 6 alkoxy, C 1 -C 6 haloakoxy
  • Embodiment 48 The compound of any one of Embodiments 1 to 43, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 5 is,
  • Embodiment 49 The compound of Embodiment 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound is N 2 ,4-dimethyl-N 5 -((R)-2-methyl-3-oxo-3-(((S)-11-oxo-2,3,10,11-tetrahydro-1H,5H- benzo[d]pyrazolo[1,2-a][1,2]diazepin-10-yl)amino)propyl)thiazole-2,5- dicarboxamide; N-((R)-2-(((S)-5,11-dioxo-2,3,10,11-tetrahydro-1H,5H-benzo[d]pyrazolo[1,2- a][1,2]diazepin-10-yl)carbamoyl)-3,3,3-trifluoropropyl)-4-methylisoxazole-5- carboxamide; 2-isobutyramido-4-methyl-N-
  • the compounds can be present in the form of one of the possible isomers or as mixtures thereof, for example as pure optical isomers, or as isomer mixtures, such as racemates and diastereoisomer mixtures, depending on the number of asymmetric carbon atoms.
  • the present invention is meant to include all such possible isomers, including racemic mixtures, diasteriomeric mixtures and optically pure forms.
  • Optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration.
  • the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.
  • the terms “salt” or “salts” refers to an acid addition or base addition salt of a compound of the invention. “Salts” include in particular “pharmaceutical acceptable salts”.
  • pharmaceutically acceptable salt or “pharmaceutically acceptable salts”, as used herein, refers to a salt or salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable.
  • the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids.
  • the organic acid or inorganic acids used to form pharmaceutically acceptable acid addition salts of compounds of the present invention include, but are not limited to, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzoic acid, benzenesulfonic acid, carbonic acid, camphor sulfonic acid, capric acid, chlorotheophyllinate, citric acid, ethanedisulfonic acid, fumaric acid, D-glycero-D-gulo-Heptonicacid, galactaric aid, galactaric acid/mucic acid, gluceptic acid, glucoheptonoic acid, gluconic acid, glucuronic acid, glutamatic acid, glutaric acid, glycolic acid, hippuric acid,
  • Salt forms of the compounds of the present invention can be converted into the free compounds by treatment with a suitable basic agent.
  • Pharmaceutically acceptable acid addition salts of compounds of the present invention include, but are not limited to, a acetate, adipate, ascorbate, aspartate, benzoate, besylatye, benzenesulfonate, bicarbonate/carbonate, bisulfate/sulfate, bromide/hydrobromide, camphor sulfonate, camsylate, caprate, chloride/hydrochloride, chlorotheophyllinate, citrate, edisylate, ethanedisulfonate, fumarate, gluceptate, glucoheptonate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulphate, malate, maleate, malon
  • Organic bases used to form pharmaceutically acceptable base addition salts of compounds of the present invention include, but are not limited to, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
  • Inorganic bases used to form pharmaceutically acceptable base addition salts of compounds of the present invention include, but are not limited to, sodium hydroxide, potassium hydroxide, ammonium hydroxide, ammonium salts and metals from columns I to XII of the periodic table.
  • Pharmaceutically acceptable base addition salts of compounds of the present invention include, but are not limited to, sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper salts; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from a basic or acidic moiety, by conventional chemical methods.
  • such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid.
  • a stoichiometric amount of the appropriate base such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like
  • Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
  • non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable.
  • Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
  • lsotopically labeled compounds have structures depicted by the formulae given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
  • Isotopes that can be incorporated into compounds of the present invention include, for example, isotopes of hydrogen. Further, incorporation of certain isotopes, particularly deuterium (i.e., 2 H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index or tolerability. It is understood that deuterium in this context is regarded as a substituent of a compound of the present invention. The concentration of deuterium, may be defined by the isotopic enrichment factor.
  • isotopic enrichment factor means the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound of this invention is denoted as being deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
  • isotopic enrichment factor can be applied to any isotope in the same manner as described for deuterium.
  • isotopes that can be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 3 H, 11 C, 13 C, 14 C, 15 N, 18 F 31 P, 32 P, 35 S, 36 Cl, 123 I, 124 I, 125 I respectively.
  • the invention includes compounds that incorporate one or more of any of the aforementioned isotopes, including for example, radioactive isotopes, such as 3 H and 14 C, or those into which non-radioactive isotopes, such as 2 H and 13 C are present.
  • isotopically labelled compounds are useful in metabolic studies (with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • an 18 F or labeled compound may be particularly desirable for PET or SPECT studies.
  • Isotopically- labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.).
  • compounds of the present invention can exist in a deuterated form as shown below:
  • Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 O, d6-acetone, d6- DMSO.
  • Compounds of the invention that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co-crystals with suitable co-crystal formers.
  • These co-crystals may be prepared from compounds of the invention by known co- crystal forming procedures. Such procedures include grinding, heating, co-subliming, co- melting, or contacting in solution compounds of the invention with the co-crystal former under crystallization conditions and isolating co-crystals thereby formed.
  • Suitable co-crystal formers include those described in WO 2004/078163. Hence the invention further provides co-crystals comprising a compound of the invention.
  • the compounds of the present invention can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
  • the compounds of the present invention may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the invention embrace both solvated and unsolvated forms.
  • solvate refers to a molecular complex of a compound of the present invention (including pharmaceutically acceptable salts thereof) with one or more solvent molecules.
  • solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like.
  • hydrate refers to the complex where the solvent molecule is water.
  • the compounds of the present invention may inherently or by design form polymorphs.
  • Any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the (R)-, (S)- or (R,S)- configuration.
  • each asymmetric atom has at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 % enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess in the (R)- or (S)- configuration.
  • Substituents at atoms with unsaturated double bonds may, if possible, be present in cis- (Z)- or trans- (E)- form.
  • a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof. Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
  • any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound.
  • a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-O,O'-p- toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid.
  • an optically active acid e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-O,O'-p- toluoyl tartaric acid, mandelic acid, malic acid
  • Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
  • HPLC high pressure liquid chromatography
  • Agents of the invention may be prepared by a reaction sequence shown in the reaction schemes of the experimental part (see hereinbelow).
  • the compounds of the invention may be prepared according to the Schemes 1-4 provided infra.
  • Compounds of the present invention were made by processes described herein and as illustrated in the Examples. The combination of various building blocks and intermediates described herein can be applied to yield compounds of the invention.
  • Non-limiting examples of synthetic schemes used to make compounds of the present invention is illustrated in Schemes 1 to 4. Further guidance can be found in the examples section.
  • Compounds of Formula (II) can be prepared as outlined in Scheme 1.
  • compounds of Formula (III) can be prepared as outlined in Scheme 2.
  • Scheme 2 Similar to the preparation of the compounds of Formula (II), the compounds of Formula (III) can be achieved by amide coupling between amines (Int-1), but in this case various mono-protected succinates (Int-4) are used as acid partners.
  • the chiral succinates intermediates (Int-4) can be prepared in enantiopure form by various methods including asymmetric hydrogenation of ⁇ - substituted acrylic acids using chiral catalysts (e.g. P. M. Donate, D. Frederico, R. daSilva, M. G. Constantino, G. Del Ponte, P. S.
  • the formed amide ester intermediates then undergo ester hydrolysis and the obtained acid intermediates can be coupled with aliphatic or aromatic amines to provide the final products of Formula (III).
  • the required chiral amine intermediates Int-1 wherein Y is CH2 can be prepared as outlined in Scheme 3.
  • Scheme 3 The tricyclic core is prepared by cyclization of 2-(2-(halomethyl)phenyl)acetates (prepared from the corresponding isochroman-3-ones - D. J. Ritchie, H. S. R. McCann, M. C. H. Standen, R. V. H. Jones, US6048998, 2000; CAN128:75194) with pyrazolidines (E. E. Boros, F. Bouvier, S.
  • the required primary amine can be introduced to such compounds by several ways. Such molecules can be transformed into ⁇ -bromo-derivatives that undergo a nucleophilic substitution with an azide which can then be reduced into the primary amine (e.g. ZHANG, Xuqing; WALL, Mark; SUI, Zhihua WO2015/160772, 2015, A1).
  • azide e.g. ZHANG, Xuqing; WALL, Mark; SUI, Zhihua WO2015/160772, 2015, A1
  • Other possibility to introduce the azide is to employ a one- step sequence utilizing the azidation of the corresponding enolate with 2,4,6- triisopropylbenzenesulfonyl azide (e.g. C. V. C.
  • amine can also be introduced by the formation of an oxime and its reduction (F. Hoffmann-Emery, R. Jakob-Roetne, A. Flohr, F. Bliss, R. Reents, Tet.
  • the enantiomerically pure amine can be obtained either by chiral resolution, by formation of separable and cleavable diastereomeric mixture (F. Hoffmann-Emery, R. Jakob-Roetne, A. Flohr, F. Bliss, R. Reents, Tet. Lett.2009, 50, 6380–6382) or preparative chiral chromatography method.
  • compositions for the therapeutic uses of compounds of the present invention, such compounds are administered either alone or as part of a pharmaceutical composition.
  • a pharmaceutical composition which comprises a compound of the present invention, or pharmaceutically acceptable salt or stereoisomer thereof, and one or more pharmaceutically acceptable carriers.
  • the composition comprises at least two pharmaceutically acceptable carriers, such as those described herein.
  • the pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration (e.g. by injection, infusion, transdermal or topical administration), and rectal administration.
  • Topical administration may also pertain to inhalation or intranasal application.
  • the pharmaceutical composition comprising a compound of the present invention can be formulated for intramuscularly, intravenously, subcutaneously, orally, pulmonary, intrathecally, topically or intranasally administration.
  • the pharmaceutical compositions of the present invention can be made up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions or emulsions). Tablets may be either film coated or enteric coated according to methods known in the art.
  • the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners.
  • diluents e.g., lactose, dextrose, sucrose
  • compositions for oral administration include a compound of the present invention in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable carriers/excipients which are suitable for the manufacture of tablets.
  • carriers/excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.
  • Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
  • the parenteral compositions e.g, intravenous (IV) formulation
  • IV intravenous
  • the parenteral compositions are aqueous isotonic solutions or suspensions.
  • the parenteral compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
  • compositions are generally prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1-50%, of the active ingredient.
  • the compound of the present invention or pharmaceutical composition thereof for use in a subject e.g., human
  • the dosage may depend upon the infusion rate at which an iv formulation is administered.
  • the therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated.
  • the above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof.
  • the compounds of the present invention can be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g., as a suspension or in aqueous solution.
  • Certain aspects and examples of the pharmaceutical compositions of the present invention are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of the present invention. Embodiment 50.
  • a pharmaceutical composition comprising a compound of Formula (I) or any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt or stereoisomer thereof, and one or more pharmaceutically acceptable carriers.
  • Embodiment 51 A pharmaceutical composition comprising a compound of Embodiment 49, or a pharmaceutically acceptable salt or stereoisomer thereof, and one or more pharmaceutically acceptable carriers.
  • Embodiment 52 The pharmaceutical composition of Embodiment 50 or Embodiment 51 comprising one or more additional therapeutic agents.
  • Pharmacology and Utility The compounds of the invention, in free form or in pharmaceutically acceptable salt form, exhibit valuable pharmacological properties, e.g.
  • the compounds of the invention may generally be useful in the treatment of an indication involving for example cells expressing high level of CD74 and/or cells involved in class II dependent antigen presentation.
  • the compounds of the invention may be useful in treating autoimmune diseases and/or disorders.
  • the compounds of the invention may be useful in the treatment and/or prevention of pemphigus vulgaris, pemphigus foliaceus, Sjoegren’s disease, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), myasthenia gravis, Hashimoto thyroiditis, thrombocytopenia purpura, myocarditis, atopic dermatitis, Goodpasture syndrome, multiple sclerosis (MS) or type I diabetes.
  • the compounds of the invention may be useful in the prevention of rejection in clinical/surgical transplantation procedures of solid organs, tissues or cell populations such as stem cells .
  • compounds of the invention might be useful in treating and/or preventing both acute and chronic graft versus host disease (GvHD) associated with transplantation of solid organs, tissues or cell populations.
  • Compounds of the invention might further be used prophylactically, e.g. as induction therapy, to prepare the host prior to transplantation of solid organs, tissues or cell populations; or compounds of the invention might further be used therapeutically after transplantation of solid organs, tissues or cell populations.
  • Non-limiting examples of transplantations are kidney tranplantation, heart transplantation (acute or chronic), and bone narrow transplantation.
  • compounds of this invention might be useful in the treatment of a donor prior to the donation of organs, tissues or cells.
  • compounds of the invention might be useful in the treatment of lymphomas in particular arising from modified B cells expressing high levels of CD74, such as non–Hodgkin's lymphoma (NHL), Burkitt Lymphoma (BL) and multiple myeloma (MM).
  • NHL non–Hodgkin's lymphoma
  • BL Burkitt Lymphoma
  • MM multiple myeloma
  • a method of treating a disease or disorder associated with the activity of signal peptide peptidase like protease 2a comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt.
  • Embodiment 54 A method of treating a disease or disorder associated with the activity of signal peptide peptidase like protease 2a (Sppl2a), wherein the method comprises administering to a subject in need of such treatment a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt.
  • Embodiment 55 A method of treating a disease or disorder associated with the activity of signal peptide peptidase like protease 2a
  • Embodiment 56 Use of a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or disorder associated with the activity of signal peptide peptidase like protease 2a (Sppl2a).
  • Embodiment 56 Use of a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof, in the treatment of a disease or disorder associated with the activity of signal peptide peptidase like protease 2a (Sppl2a).
  • Embodiment 57 Use of a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or disorder associated with the activity of signal peptide peptidase like protease 2a (Sppl2a).
  • Embodiment 58 A method of treating an autoimmune disease in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof.
  • Embodiment 59 A method of treating an autoimmune disease in a subject in need thereof, wherein the method comprises administering to the subject a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof.
  • Embodiment 60 A method of treating an autoimmune disease in a subject in need thereof, wherein the method comprises administering to the subject a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof.
  • Embodiment 61 Use of a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of an autoimmune disease.
  • Embodiment 61 Use of a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof, in the treatment of an autoimmune disease.
  • Embodiment 62 A compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof, for use in the treatment of an autoimmune disease.
  • Embodiment 63 A compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof, for use in the treatment of an autoimmune disease.
  • autoimmune disease is Sjoegren’s disease, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), lupus nephritis, systemic sclerosis, multiple sclerosis (MS), autoimmune hepatitis, uveitis, pemphigus vulgaris, pemphigus foliaceus,myasthenia gravis, Hashimoto thyroiditis, thrombocytopenia purpura, myocarditis, atopic dermatitis, Goodpasture syndrome, or type I diabetes.
  • SLE systemic lupus erythematosus
  • RA rheumatoid arthritis
  • MS multiple sclerosis
  • autoimmune hepatitis uveitis, pemphigus vulgaris, pemphigus foliaceus,myasthenia gravis, Hashimoto thyroiditis, thrombocytopenia purpura, myocarditis, atopic dermatiti
  • Embodiment 64 The method of any one of Embodiments 53, 54, 58 or 59, the use of a compound in any one of Embodiments 55, 56, 60 or 61, or the compound for the use of Embodiments 57 or 62, wherein the autoimmune disease is multiple sclerosis (MS), Sjoegren’s disease, systemic rheumatoid arthritis (RA), lupus nephritis or systemic sclerosis.
  • MS multiple sclerosis
  • RA systemic rheumatoid arthritis
  • Embodiment 65 Embodiment 65.
  • Embodiment 53, 54, 58 or 59 The method of any one of Embodiments 53, 54, 58 or 59, the use of a compound in any one of Embodiments 55, 56, 60 or 61, or the compound for the use of Embodiments 57 or 62, wherein the autoimmune disease is multiple sclerosis (MS).
  • Embodiment 66 A method of treating a disease associated with the expression of high levels of CD74 in B cells in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof.
  • Embodiment 67 A method of treating a disease associated with the expression of high levels of CD74 in B cells in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof.
  • a method of treating a disease associated with the expression of high levels of CD74 in B cells in a subject comprising administering to the subject a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof.
  • Embodiment 68 Use of a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease associated with the expression of high levels of CD74 in B cells in a subject.
  • Embodiment 69 Use of a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof, in the treatment of a disease associated with the expression of high levels of CD74 in B cells in a subject.
  • Embodiment 70 Use of a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof, in the treatment of a disease associated with the expression of high levels of CD74 in B cells in a subject.
  • Embodiment 71. The method of any one of Embodiments 66 or 67, the use of a compound in any one of Embodiments 68 or 69, or the compound for the use of Embodiment 70, wherein the a B-cell lymphoma is non–Hodgkin's lymphoma (NHL), Burkitt Lymphoma (BL) and multiple myeloma (MM).
  • HNL Hodgkin's lymphoma
  • BL Burkitt Lymphoma
  • MM multiple myeloma
  • a method of treating a B-cell lymphoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof.
  • Embodiment 73 A method of treating a B-cell lymphoma in a subject in need thereof, wherein the method comprises administering to the subject a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof.
  • Embodiment 74. Use of a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a B-cell lymphoma.
  • Embodiment 75 Use of a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a B-cell lymphoma.
  • Embodiment 76 A compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof, for use in the treatment of a B-cell lymphoma.
  • Embodiment 77 The method of any one of Embodiments 72 or 73, the use of a compound in any one of Embodiments 74 or 75, or the compound for the use of Embodiment 76, wherein the a B-cell lymphoma is non–Hodgkin's lymphoma (NHL), Burkitt Lymphoma (BL) and multiple myeloma (MM).
  • NHL Hodgkin's lymphoma
  • BL Burkitt Lymphoma
  • MM multiple myeloma
  • Embodiment 78 A method for treating graft versus host disease (GvHD) in a subject after transplantation, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof, wherein the transplantation is the transplantation of a solid organ, a tissue or a cell population.
  • Embodiment 79. A method for treating graft versus host disease (GvHD) in a subject after transplantation, wherein the method comprises administering to the subject a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof, wherein the transplantation is the transplantation of a solid organ, a tissue or a cell population.
  • Embodiment 80 A method for treating graft versus host disease (GvHD) in a subject after transplantation, wherein the method comprises administering to the subject a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof, wherein the
  • a method for preventing graft versus host disease (GvHD) in a subject after transplantation comprises administering to the subject prior to transplantation a therapeutically effective amount of a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof, wherein the transplantation is the transplantation of a solid organ, a tissue or a cell population.
  • Embodiment 81 A method for preventing graft versus host disease (GvHD) in a subject after transplantation, wherein the method comprises administering to the subject prior to transplantation a compound of any one of Embodiments 1 to 49, or a pharmaceutically acceptable salt thereof, wherein the transplantation is the transplantation of a solid organ, a tissue or a cell population.
  • Embodiment 82 Use a compound of any one of Embodiments 1 to 49 for treating graft versus host disease (GvHD) in a subject after transplantation, wherein the transplantation is the transplantation of a solid organ, a tissue or a cell population.
  • Embodiment 83 Use a compound of any one of Embodiments 1 to 49 in the manufacture of a medicament for treating graft versus host disease (GvHD) in a subject after transplantation, wherein the transplantation is the transplantation of a solid organ, a tissue or a cell population.
  • Embodiment 84 Use a compound of any one of Embodiments 1 to 49 for treating graft versus host disease (GvHD) in a subject after transplantation, wherein the transplantation is the transplantation of a solid organ, a tissue or a cell population.
  • Embodiment 87 The method of any one of Embodiments 78 to 81, the use of a compound in any one of Embodiments 82 or 83, or the compound for the use of Embodiment 84, wherein the transplantation is bone marrow transplantation.
  • Embodiment 87 The method of any one of Embodiments 78 to 81, the use of a compound in any one of Embodiments 82 or 83, or the compound for the use of Embodiment 84, wherein the transplantation is stem cell transplantation.
  • Embodiment 88 The method of any one of Embodiments 78 to 81, the use of a compound in any one of Embodiments 82 or 83, or the compound for the use of Embodiment 84, wherein the transplantation is stem cell transplantation.
  • Embodiment 78 to 81 The method of any one of Embodiments 78 to 81, the use of a compound in any one of Embodiments 82 or 83, or the compound for the use of Embodiment 84, wherein the transplantation is hematopoietic stem cell transplantation.
  • Embodiment 89 The method of any one of Embodiments 78 to 81, the use of a compound in any one of Embodiments 82 or 83, or the compound for the use of Embodiment 84, wherein the transplantation is transplantation of a tissue.
  • a therapeutic agent is, for example, a chemical compound, peptide, antibody, antibody fragment or nucleic acid, which is therapeutically active or enhances the therapeutic activity when administered to a patient in combination with a compound of the present invention.
  • Compounds of the invention may be administered as the sole active ingredient or together with other drugs useful against neoplastic diseases, inflammatory disorders, in immunomodulating regimens or in induction therapy to prevent GvHD and transplant rejection.
  • the compounds of the invention may be used in combination e.g. with cyclosporins, rapamycins or ascomycins, or their immunosuppressive analogs or derivatives, e.g.
  • cyclosporin A cyclosporin G, Isa tx247, FK-506, sirolimus or everolimus
  • corticosteroids e.g. prednisone; cyclophosphamide; azathioprene; methotrexate; gold salts; sulfasalazine, antimalarials; leflunomide; mizoribine; mycophenolic acid; mycophenolate mofetil; 15-deoxyspergualine; with a S1P receptor agonist e.g FTY720 or an analogue thereof;with immuno-suppressive monoclonal antibodies, e.g. monoclonal antibodies to leukocyte receptors, e.g.
  • a compound of formula I may also be used in combination with other antiproliferative agents.
  • antiproliferative agents include, but are not limited to aromatase inhibitors, antiestrogens, topoisomerase I inhibitors, topoisomerase II inhibitors, microtubule active agents, alkylating agents, histone deacetylase inhibitors, farnesyl transferase inhibitors, COX-2 inhibitors, MMP inhibitors, mTOR inhibitors, antineoplastic antimetabolites, platin compounds, compounds decreasing the protein kinase activity and further anti-angiogenic compounds, gonadorelin agonists, anti-androgens, bengamides, bisphosphonates, antiproliferative antibodies and temozolomide (TEMODAL).
  • TEMODAL temozolomide
  • Phase separator Biotage - Isolute Phase separator (Part Nr: 120-1908-F for 70 mL and Part Nr: 120-1909-J for 150 mL)
  • TLC conditions R f values for TLC are measured on 5 x 10 cm TLC plates, silica gel F 254 , Merck, Darmstadt, Germany.
  • HPLC conditions Method a: HPLC Instrument: Agilent 1100 series; Column: Waters X-Bridge C182.5 ⁇ m 3*30 mm, Eluent A: water + 0.1% TFA, B: ACN+0.1% TFA, Gradient 10 to 98% B in 3 min, Flow: 1.4 mL/min Method b: HPLC Instrument: Agilent 1100 series; Column: Waters X-Bridge C182.5 ⁇ m 3*50 mm, Eluent A: water + 0.1% TFA, B: ACN+0.1% TFA, Gradient 10 to 98% B in 8.6 min, Flow: 1.4 mL/min Method c: HPLC Instrument: Agilent 1200 series; Column: Waters Eclipse XDB-C181.8 ⁇ m 2.1*30 mm, Eluent A: water + 0.1% TFA, B: ACN+0.1% TFA, Gradient 5 to 100% B in 3 min, Flow: 1.4 mL/min Method d: HPLC Instrument:
  • LCMS method a UPLC/MS Instrument: Waters UPLC Acquity; column: Acquity HSS T31.8 ⁇ m 2.1* 50 mm at 50°C, Eluent A: water + 0.05 % HCOOH + 3.75 mM ammonium acetate, B: ACN + 0.04 % HCOOH, Gradient: 2 to 98 % B in 1.4 min, Flow: 1.2 mL/min (2 min)
  • LCMS method b UPLC/MS Instrument: Waters UPLC Acquity; column: Acquity HSS T31.8 ⁇ m 2.1* 50 mm at 60°C, Eluent A: water + 0.05 % HCOOH + 3.75 mM ammonium acetate, B: ACN + 0.04 % HCOOH, Gradient: 5 to 98 % B in 1.4 min, Flow: 1 mL/min (2 min)
  • Step 2 Pyrazolidine dihydrochloride (14.2 g, 98 mmol) was added at rt to a solution of methyl 2- (2-(chloromethyl)phenyl)acetate (19.4 g, 98 mmol) in DMF (500 mL) followed by DIPEA (85 mL, 488 mmol), sodium iodide (14.6 g, 98 mmol) and sodium acetate (32.0 g, 391 mmol). The suspension was stirred at rt for 16 h. The reaction mixture was concentrated, the crude material was dissolved in ethyl acetate and washed with sat. NaHCO 3 solution.
  • Step 3 1M LiHMDS solution in THF (93 mL, 93 mmol) was added dropwise at 0 °C to a solution of 2,3,5,10-tetrahydrobenzo[d]pyrazolo[1,2-a][1,2]diazepin-11(1H)-one (14.0 g, 62 mmol) and isopentyl nitrite (10.8 mL, 81 mmol) in THF (750 mL), and the solution was stirred at 0 °C for 2 h. The reaction mixture was concentrated and dissolved in ethyl acetate, washed with sat.
  • Step 4 Zinc dust (10.9 g, 166 mmol) was added at rt to a solution of (Z) and (E)-10- (hydroxyimino)-2,3,5,10-tetrahydrobenzo[d]pyrazolo[1,2-a][1,2]diazepin-11(1H)-one (9.6 g, 42 mmol) in AcOH (300 mL) and a 10% HCl aq. solution (300 mL) and the reaction mixture was stirred at rt for 2 h.
  • Step 5 Boc 2 O (9.0 g, 41 mmol) and Na 2 CO 3 (13.0 g, 124 mmol) were added at rt to a solution of 10-amino-2,3,5,10-tetrahydrobenzo[d]pyrazolo[1,2-a][1,2]diazepin-11(1H)-one (29.2 g, 41 mmol) in dioxane (400 mL) and water (200 mL), and the resulting mixture was stirred at rt for 16 h. The mixture was concentrated and treated with ethyl acetate and sat. NaHCO 3 solution.
  • Step 6 The two enantiomers of tert-butyl 11-oxo-1,2,3,5,10,11- hexahydrobenzo[d]pyrazolo[1,2-a][1,2]diazepin-10-ylcarbamate were separated by chiral HPLC (Thar SFC-200 instrument, mobile phase: scCO 2 /EtOH 85:15, column: Chiralcel OD-H, 30 x 250 mm) to provide tert-butyl (S)-(11-oxo-2,3,10,11-tetrahydro-1H,5H-benzo[d]pyrazolo[1,2- a][1,2]diazepin-10-yl)carbamate (enantiomeric excess ⁇ 99.5%) and tert-butyl (R)-(11-oxo- 2,3,10,11-tetrahydro-1H,5H-benzo[d]pyrazolo[1,2-a][
  • Step 7 tert-butyl (S)-(11-oxo-2,3,10,11-tetrahydro-1H,5H-benzo[d]pyrazolo[1,2-a][1,2]diazepin- 10-yl)carbamate (17.7 g, 56 mmol) was treated with 4M HCl in dioxane (250 mL) and the mixture was stirred at rt for 1 h. The reaction mixture was concentrated to yield (S)-10-amino- 2,3,5,10-tetrahydro-1H,11H-benzo[d]pyrazolo[1,2-a][1,2]diazepin-11-one (int-A1) as an HCl salt.
  • the reaction mixture was stirred at reflux for 2 h and, after cooling to room temperature, was filtered over a pad of Celite ® . Solvent was removed in vacuo and the residue partitioned between 2N HCl and CH 2 Cl 2 . The organic layer was then treated with sat. NaHCO 3 until basic pH was reached. The water layer was washed with CH 2 Cl 2 , acidified with 2N HCl to pH 1 and extracted with CH 2 Cl 2 . The organic layer was washed with brine, dried (Na 2 SO 4 ) and concentrated to give 2-(2-ethoxy- 2-oxoethyl)-6-fluorobenzoic acid.
  • the crude intermediate was dissolved in THF (100 mL) and cold (0 °C) NaBH 4 (3.2 g, 84 mmol) in H 2 O (34 mL) was added at -15 °C. After stirring at -15 °C for 1 h, the mixture was quenched by addition of 1N HCl and extracted with Et 2 O. Organic layers were washed with sat. NaHCO 3 , water and brine, dried (Na 2 SO 4 ) and concentrated. The crude intermediate was heated together with TsOH.H 2 O (399 mg, 2.1 mmol) in PhMe (100 mL) at 80°C for 1 h.
  • Step 3 Thionyl chloride (0.88 mL, 12.0 mmol) was added dropwise at 0 °C to a suspension of 8- fluoroisochroman-3-one (1.0 g, 6.0 mmol) in MeOH (10 mL). The solution was stirred at 0 °C for 1 h, then at rt for 16 h. The reaction mixture was treated with toluene, washed with water followed by a sat. NaHCO 3 until pH 6-7. The combined organic layers were washed with brine, dried (Na 2 SO 4 ) and concentrated to give methyl 2-(2-(chloromethyl)-3-fluorophenyl)acetate which was used directly for the next step.
  • Step 4 A mixture of methyl 2-(2-(chloromethyl)-3-fluorophenyl)acetate (1.0 g, 4.6 mmol), pyrazolidine dihydrochloride (0.67 g, 4.6 mmol), DIPEA (4.0 mL, 23 mmol), NaI (0.69 g, 4.6 mmol) and NaOAc (1.52 g, 18.5 mmol) in DMF (45 mL) was stirred in a microwave oven at 200 °C for 10 min. After cooling to rt, the reaction mixture was treated with ethyl acetate and extracted with sat. NaHCO 3 .
  • Step 5 1M LiHMDS in THF (3.4 mL, 3.4 mmol) was added dropwise at 0 °C to a mixture of 6- fluoro-2,3,5,10-tetrahydrobenzo[d]pyrazolo[1,2-a][1,2]diazepin-11(1H)-one (300 mg, 1.4 mmol) and isopentylnitrite (330 ⁇ L, 2.5 mmol) in THF (10 mL). The reaction was stirred at 0 °C for 2 h, before it was treated with sat. NaHCO 3 solution and extracted with ethyl acetate.
  • Step 6 A mixture of (E/Z)-6-fluoro-10-(hydroxyimino)-2,3,5,10-tetrahydrobenzo[d]pyrazolo[1,2- a][1,2]diazepin-11(1H)-one (141 g, 566 mmol) was hydrogenated (4 bar) over 10% Pd/C (16 g) in a mixture of ethanol (3.3 L) and 1M HCl (0.9 L) at rt for 16 h.
  • Step 7 A solution of Boc 2 O (151 g, 680 mmol) in CH 2 Cl 2 (300 mL) was added at rt to a solution of 10-amino-6-fluoro-2,3,5,10-tetrahydro-1H,11H-benzo[d]pyrazolo[1,2-a][1,2]diazepin-11-one (HCl salt, 154 g, 567 mmol) and DIPEA (352 mL, 1984 mmol) in CH 2 Cl 2 (3.4 L). The mixture was stirred at rt for 16 h. It was then ttreated with water, the aqueous phase was extracted with CH 2 Cl 2 and the combined organic phases were dried (Na 2 SO 4 ) and concentrated.
  • Step 8 chiral separation
  • the two enantiomers of tert-butyl (6-fluoro-11-oxo-2,3,10,11- tetrahydro-1H,5H-benzo[d]pyrazolo[1,2-a][1,2]diazepin-10-yl)carbamate were separated by chrial HPLC (Bayer CC50 SMB unit, mobile phase: acetonitrile/methanol 1:1, column: Chiralpak AD, 8 x (10 x 100 mm)) to provide tert-butyl (S)-(6-fluoro-11-oxo-2,3,10,11-tetrahydro-1H,5H- benzo[d]pyrazolo[1,2-a][1,2]diazepin-10-yl)carbamate (enantiomeric excess > 99.5%) and tert- butyl (R)-(6-fluoro-11-oxo-2,3,10,11-tetrahydro-1
  • Step 9 A mixture of tert-butyl (S)-(6-fluoro-11-oxo-2,3,10,11-tetrahydro-1H,5H- benzo[d]pyrazolo[1,2-a][1,2]diazepin-10-yl)carbamate (1.3 g, 4.0 mmol) in CH 2 Cl 2 (20 mL) was treated at 0 °C with 4M HCl in dioxane (20 mL, 80 mmol) and the reaction mixture was stirred at 0 °C for 2 h.
  • Step 2 4M HCl in dioxane (151 mL, 604 mmol) was added to a solution of tert-butyl (S)-(5,11- dioxo-2,3,10,11-tetrahydro-1H,5H-benzo[d]pyrazolo[1,2-a][1,2]diazepin-10-yl)carbamate (10 g, 30 mmol) in CH 2 Cl 2 (151 mL) and the mixture was stirred at rt for 2 h. The reaction mixture was then concentrated and suspended in Et 2 O followed by evaporation to remove residual HCl.
  • Step 2 A solution of di-tert-butyl hydrazine-1,2-dicarboxylate (18.6 g, 80 mmol) in dry DMF (65 mL) was added dropwise at 0 °C to a suspension of NaH (60% dispersion in oil, 6.7 g, 168 mmol) in dry DMF (40 mL) and the suspension was stirred at rt for 1 h. After addition of cyclopropane-1,1-diylbis(methylene) dimethanesulfonate (20.7 g, 80 mmol) the reaction mixture was stirred at rt for 16 h. It was then poured onto ice and water (1.3 L).
  • Step 3 Hydrobromic acid solution (33 wt % in AcOH, 38.5 mL, 0.22 mol) was added slowly at 0 °C to a solution of di-tert-butyl 5,6-diazaspiro[2.4]heptane-5,6-dicarboxylate (12 g, 40 mmol) in Et 2 O (200 mL) and the mixture was stirred at rt for 16 h. After cooling to 0 °C, the solid was filtered off, washed with Et 2 O and dried in vacuum to give 5,6-diazaspiro[2.4]heptane dihydrobromide.
  • Step 5 1M LiHMDS in THF (26 mL, 26 mmol) was added dropwise at 0 °C to a suspension of 1H-spiro[benzo[d]pyrazolo[1,2-a][1,2]diazepine-2,1'-cyclopropane]-5,11(3H,10H)-dione (4.1 g, 17 mmol) and isopentyl nitrite (3.4 mL, 26 mmol) in THF (34 mL). The reaction mixture was stirred at rt for 2 h.
  • Step 6 4M HCl (4.3 mL, 17 mmol) was added at rt to a mixture of crude (Z,E)-10- (hydroxyimino)-1H-spiro[benzo[d]pyrazolo[1,2-a][1,2]diazepine-2,1'-cyclo-propane]- 5,11(3H,10H)-dione (4.6 g, 17.0 mmol) in AcOH (92 mL). The mixture was then cooled to 0 °C and Zn powder (4.5 g, 68 mmol) was added slowly. After the addition, the reaction mixture was stirred at rt for 1.5 h.
  • Boc 2 O (76 g, 347 mmol) was added at room temperature to rac.10-amino-1H,3H,5H- spiro[benzo[d]pyrazolo[1,2-a][1,2]diazepine-2,1'-cyclopropane]-5,11(10H)-dione (68 g, 231 mmol) and Na 2 CO 3 (110 g, 1.04 mol) in dioxane/water (1:1 mixture, 1.4 L) and the resulting mixture was stirred at rt for 2 h. The formed precipitate was filtered off, washed twice with water and dried under vacuum.
  • Step 1 To a solution of cyclopropane-1,1-diyldimethanol (25.0 g, 245 mmol) in CH 2 Cl 2 (250 mL) was added Et 3 N (136 mL, 979 mmol) and the reaction mixture was cooled to 0 °C. A solution of MsCl (57.2 mL, 734 mmol) in CH 2 Cl 2 (160 mL) was added dropwise and the cooling bath was removed. After stirring at rt for 16 h, 1N HCl (900 mL) was added and the mixture was extracted with CH 2 Cl 2 , the combined organic layers were washed with brine, and dried (Na 2 SO 4 ).
  • Step 2 A solution of di-tert-butyl hydrazine-1,2-dicarboxylate (18.6 g, 80 mmol) in anhydrous DMF (65 mL) was added at 0 °C to a suspension of NaH (6.72 g, 168 mmol) in anhydrous DMF (40 mL). The suspension was stirred at rt for 1 h before solid cyclopropane-1,1- diylbis(methylene) dimethanesulfonate (20.7 g, 80 mmol) was added and the resulting mixture was stirred at rt for 16 h.
  • Step 3 Hydrobromic acid solution (33 wt % in AcOH, 38.5 mL) was slowly added at 0 °C to a solution of di-tert-butyl 5,6-diazaspiro[2.4]heptane-5,6-dicarboxylate (11.9 g, 40 mmol) in Et 2 O (200 mL) and the mixture was stirred at rt for 16 h. The reaction mixture was then cooled to 0 °C and filtered off. The solid was washed with Et 2 O and dried in high vacuum to give 5,6- diazaspiro[2.4]heptane dihydrobromide.
  • Step 4 A mixture of methyl 2-(2-(chloromethyl)phenyl)acetate (2.38 g, 12 mmol), 5,6- diazaspiro[2.4]heptane dihydrobromide (3.74 g, 14.4 mmol), anhydrous MeOH (30 mL) and DIPEA (10.5 mL, 60 mmol) was heated at 150 °C for 5 h in a microwave oven.
  • Step 5 Isoamyl nitrite (0.646 mL, 4.80 mmol) was added at 0 °C to a solution of 5,10-dihydro- 1H-spiro[benzo[d]pyrazolo[1,2-a][1,2]diazepine-2,1'-cyclopropan]-11(3H)-one (913 mg, 4 mmol) in THF (10 mL) followed by addition of LiHMDS (1M in THF, 5.60 mL, 5.60 mmol). After stirring the reaction mixture at 0 °C for 2 h, the reaction was quenched by addition of water and the mixture was concentrated.
  • Step 6 Zinc powder (1.0 g, 15.9 mmol) was slowly added at 0 °C to a mixture of 4N HCl (1 mL) and (Z,E)-10-(hydroxyimino)-5,10-dihydro-1H-spiro[benzo[d]pyrazolo[1,2-a][1,2]diazepine-2,1'- cyclopropan]-11(3H)-one (1.03 g, 3.98 mmol) in AcOH (20 mL) and the reaction mixture was stirred at rt for 2.5 h. The mixture was then filtered to remove zinc and the solids were washed with CH 2 Cl 2 .
  • Step 2 1M NaHMDS in THF (8.68 mL, 8.68 mmol) was added dropwise at -78 °C to a solution of (S)-4-benzyl-3-(2-cyclopropylacetyl)oxazolidin-2-one (1.5 g, 5.78 mmol) in THF (8 mL). After stirring at -78 °C for 1 h, tert-butyl 2-bromoacetate (1.55 mL, 10.41 mmol) was added and the mixture was stirred at -78°C for 1 h. It was then quenched by addition of sat. NH 4 Cl and allowed to warm to rt.
  • Step 3 TFA (4.54 ul, 58.9 mmol) was added at rt to a solution of tert-butyl (S)-4-((S)-4-benzyl-2- oxooxazolidin-3-yl)-3-cyclopropyl-4-oxobutanoate (1.1 g, 2.95 mmol) in CH 2 Cl 2 (25 mL) and the solution was stirred at rt for 1 h. The reaction mixture was then concentrated, the residue dissolved in CH 2 Cl 2 and concentrated again.
  • Step 4 Ethyl chloroformate (480 mg, 4.42 mmol) was added at 0 °C to a solution of (S)-4-((S)-4- benzyl-2-oxooxazolidin-3-yl)-3-cyclopropyl-4-oxobutanoic acid (1.275 mg, 4.02 mmol) and triethylamine (672 ⁇ L, 4.82 mmol) in acetone (40 mL) and the reaction mixture was stirred at 0 °C for 1 h. Then a solution of NaN 3 (522 mg in 10 mL H 2 O) was added to the reaction mixture at 0 °C and the mixture was stirred at 0 °C for 1 h.
  • NaN 3 522 mg in 10 mL H 2 O
  • Step 5 Hydrogen peroxide (1.1 mL, 10.81 mmol) was added at 0 °C to a mixture of tert-butyl ((R)-3-((S)-4-benzyl-2-oxooxazolidin-3-yl)-2-cyclopropyl-3-oxopropyl)carbamate (1.4 g, 3.60 mmol) in THF (8 mL), followed by LiOH (302 mg, 7.21 mmol) and water (0.7 mL) and the reaction mixture was stirred at 0 °C for 2.5 h. The reaction mixture was then treated at 0 °C with sat. NaHSO 3 (4 mL) and sat. NaHCO 3 (10 mL).
  • Step 2 LiHMDS (29.8 mL, 29.8 mmol) was added dropwise at 0 °C to a mixture of 3-amino-N- ((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)-N-methylpropanamide (2.2 g, 9.31 mmol) and LiCl (1.579 g, 37.2 mmol) in THF (44 mL). After 1 h stirring at 0 °C, 1-iodopropane (1.364 mL, 13.96 mmol) was added slowly and the mixture was stirred at 0 °C for 6 h.
  • Step 4 Na 2 CO 3 (415 mg, 3.91 mmol) and Boc 2 O (0.30 mL, 1.30 mmol) were added to a solution of (R)-2-(aminomethyl)pentanoic acid in dioxane (2 mL) and water (1 mL) and the reaction mixture stirred at rt for 2 days. The reaction mixture was then washed with CH 2 Cl 2 , acidified with 1N HCl and extracted with ethyl acetate. The organic layers were dried (MgSO 4 ) and concentrated to give (R)-2-(((tert-butoxycarbonyl)amino)methyl)pentanoic acid (int-L4).
  • Step 1 Oxalyl chloride (1.844 mL, 21.07 mmol) was added dropwise at rt to a stirred solution of 4-methoxybutanoic acid (2.37 g, 20.06 mmol) in CH 2 Cl 2 (100 mL), followed by addition of a drop of DMF. The resulting solution was stirred at rt for 1 h. The reaction mixture was concentrated to provide 4-methoxybutanoyl chloride which was used directly in the next step.
  • Step 2 n-Butyllithium (1.6 M in hexanes) (12.54 mL, 20.06 mmol) was added dropwise at -78 °C to a stirred solution of (S)-4-benzyloxazolidin-2-one (3.55 g, 20.06 mmol) in THF (201 mL) and the resulting solution was stirred at -78 °C for 15 min.4-Methoxybutanoyl chloride (2.74 g, 20.06 mmol) in THF (5 mL) was then added dropwise at -78 °C and the reaction mixture stirred for 1 h at -78 °C before it was quenched with sat. NaHCO 3 solution (100 mL).
  • Step 3 LiHMDS (1M in PhMe) (3.97 mL, 3.97 mmol) was added at -78 °C to a stirred solution of (S)-4-benzyl-3-(4-methoxybutanoyl)oxazolidin-2-one (1 g, 3.61 mmol) in THF (36.1 mL) and the resulting solution was warmed to -10 °C and stirred for 15 minutes. After cooling to -78 °C, N,N- dibenzyl-1-methoxymethanamine (1.74 g, 7.21 mmol) was added, followed by addition of titanium(IV) chloride (0.080 mL, 0.721 mmol).
  • Step 4 (S)-4-benzyl-3-((R)-2-((dibenzylamino)methyl)-4-methoxybutanoyl)oxazolidin-2-one (1.26 g, 2.59 mmol) in MeOH (25 mL) was hydrogenated using H 2 (4 bar) and Pd/C (10 mol %) for 2 h at room temperature (0.18 g). The reaction mixture was then treated with Boc 2 O (0.9 g, 4.1 mmol) to give tert-butyl ((R)-2-((S)-4-benzyl-2-oxooxazolidine-3-carbonyl)-4- methoxybutyl)carbamate.
  • N,N-Dibenzyl-1-methoxymethanamine (Bn 2 NCH 2 OMe) was obtained using the following procedure Potassium carbonate (21.0 g, 152 mmol) and formaldehyde (3.81 g, 127 mmol) were added to a solution of dibenzylamine (10.0 g, 50.7 mmol) in MeOH (10 mL) and the reaction mixure was stirred at rt for 4 h. K 2 CO 3 (21.0 g, 152 mmol) was then added and the mixture was stirred at rt for 16 h.
  • Step 2 1M NaHMDS in THF (5.9 mL, 5.9 mmol) was added dropwise at -78 °C to a solution of (S)-4-benzyl-3-(2-cyclopropylacetyl)oxazolidin-2-one (1.0 g, 3.9 mmol) in THF (30 mL). After stirring at -78 °C for 1 h, tert-butyl 2-bromoacetate (1.2 mL, 7.8 mmol) was added and the solution was stirred for additional 1 h at -78 °C. The reaction mixture was treated with sat. aq.
  • Step 3 Hydrogen peroxide (30% in water; 0.88 mL, 8.6 mmol) followed by LiOH (0.18 g, 4.3 mmol) in water (1 mL) were added at 0 °C to a solution of tert-butyl (S)-4-((S)-4-benzyl-2- oxooxazolidin-3-yl)-3-cyclopropyl-4-oxobutanoate (0.8 g, 2.1 mmol) in THF (20 mL) and the reaction mixture was stirred at 0 °C for 2 h. It was then treated with sat. aq. NaHSO 3 (20 mL) and sat. aq.
  • Step 2 1M LiOH aq. solution (16.5 mL, 16.5 mmol) was added to a solution of methyl 2- isobutyramido-4-methylthiazole-5-carboxylate (400 mg, 1.65 mmol) in THF (16 mL). The mixture mixture was stirred for 16 h at rt. THF was removed under reduced pressure and the residue was washed with Et 2 O. The aqueous phase was acidified with HCl, and the resulting white suspension was stirred for 30 min. and then filtered cold and dried on HV to give 2- isobutyramido-4-methylthiazole-5-carboxylic acid (int-EC1).
  • int-EC1 2- isobutyramido-4-methylthiazole-5-carboxylic acid
  • Step 2 A solution of 5-(tert-butyl) 2-ethyl 4-methylthiazole-2,5-dicarboxylate (500 mg, 1.84 mmol) in 2M solution of ethanamine in EtOH (27.6 mL, 55.2 mmol) was stirred at room temperature for 16 h. The reaction mixture was treated with ethyl acetate and washed with sat. NaHCO 3 and 1N HCl. The organic phase was dried (MgSO 4 ) and concentrated to give tert-butyl 2-(ethylcarbamoyl)-4-methylthiazole-5-carboxylate.
  • Step 2 (6-(Trifluoromethyl)pyridin-3-yl)boronic acid (4.24 g, 22.2 mmol), Pd(PPh 3 ) 4 (1.17 g, 1.0 mmol) and 2M Na 2 CO 3 aq. solution (25 mL, 1.88 mmol) were added to a mixture of 2,4- dichlorothiazole-5-carboxylic acid (4 g, 20.20 mmol) and DME (150 mL). The reaction mixture was stirred at 80 °C for 7 h in microwave oven. The reaction mixture was quenched with water and extracted with ethyl acetate. The aqueous phase was acidified with concentrated HCl and extracted with ethyl acetate.
  • Step 2 LiOH in H 2 O (24.66 mL, 24.66 mmol) was added at rt to a mixture of ethyl 4-methyl-2-(6- (trifluoromethyl)pyridin-3-yl)thiazole-5-carboxylate (5.2 g, 16.44 mmol) in ethanol (110 mL) and the mixture was stirred at rt for 1.5 h. The solvent was removed, the residue was then treated with water and the solution was then acidied with 2N HCl. The resulting suspension was filtered off and the solid was dried in vacuum to give 4-methyl-2-(6-(trifluoromethyl)pyridin-3-yl)thiazole- 5-carboxylic acid (int-EC7).
  • Step 2 3-Methylisoxazole-5-carbothioamide (0.858 g, 5.19 mmol) was added to a solution of tert-butyl 2-chloro-3-oxobutanoate (1 g, 5.19 mmol) in t-BuOH (20 mL) and the reaction mixture was stirred at 90 °C for 16 h. After cooling to rt, the reaction mixture was concentrated and the crude product was purified by column chromatography (0-40% ethyl acetate in cyclohexane) to give tert-butyl 4-methyl-2-(3-methylisoxazol-5-yl)thiazole-5-carboxylate.
  • Step 1 Ethylenglycol (4.6 mL, 82 mmol) and p-TsOH (260 mg, 1.37 mmol) were added to a solution of 2,4-dichlorothiazole-5-carbaldehyde (5.0 g, 27.5 mmol) in toluene (60 mL) and the mixture was stirred at reflux for 5 h. The reaction was cooled to rt, poured into 20% Na 2 CO 3 (120 mL) and the solution was extracted twice with ethyl acetate. The combined organic phase was washed with H 2 O and brine, dried (Na 2 SO 4 ) and concentrated.
  • Step 2 n-Butyllithium (1.6M hexane solution, 8.7 mL, 13.9 mmol) was added at -78 °C to a solution of 2,4-dichloro-5-(1,3-dioxolan-2-yl)thiazole (3.0 g, 13.27 mmol) in THF (20 mL) and the mixture was stirred at -78 °C for 20 min. Solid carbon dioxide (20 g) was then introduced and the reaction mixture was gradually warmed to rt and stirred at rt for 16 h.
  • Step 3 Propan-2-amine (1.2 mL, 14.0 mmol) and EDC (3.65 g, 19.10 mmol) were added to a mixture of 4-chloro-5-(1,3-dioxolan-2-yl)thiazole-2-carboxylic acid (3.0 g, 12.73 mmol), HOBt (2.43 mg, 15.28 mmol) and Et 3 N (2.3 mL, 16.55 mmol) in CH 2 Cl 2 (120 mL) and the suspension was stirred overnight at rt. The reaction mixture was concentrated and treated with ethyl acetate and 1N HCl. The combined organic layer was washed with sat.
  • Step 4 6M HCl (3.0 mL, 18.07 mmol) was added at rt to a solution of 4-chloro-5-(1,3-dioxolan- 2-yl)-N-isopropylthiazole-2-carboxamide (1.0 g, 3.61 mmol) in Et 2 O (36.0 mL) and the solution was stirred for 16 h at rt. Then the pH of the mixture was adjusted to 7-8 with sat. NaHCO 3 and the organic layer was separated.
  • Step 5 A mixture of sulfamic acid (815 mg, 8.38 mmol) and NaClO 2 (947 mg, 8.38 mmol) in water (5 mL) was added to a solution of 4-chloro-5-formyl-N-isopropylthiazole-2-carboxamide (1.3 g, 2.15 mmol) in THF (33 mL) and water (18 mL) and the mixture was stirred for 16 h at rt. The reaction was quenched with H 2 O and the mixture was extracted twice with Et 2 O. The organic layers were combined and washed with 0.5M NaOH. The water phase containing the product was acidified with conc.
  • Step 1 A mixture of cesium carbonate (615 mg, 1.89 mmol), cyclopent-1-en-1-ylboronic acid (116 mg, 1.04 mmol) and methyl 2,4-dichlorothiazole-5-carboxylate (200 mg, 0.94 mmol) in THF (2.4 mL) and water (2.4 mL) was purged with argon for 5 min. before Pd(dppf)Cl 2 .CH 2 Cl 2 (77 mg, 0.094 mmol) was added and the resulting mixture was heated in a microwave at 80 °C for 1 h. After cooling to rt, the reaction mixture was concentrated and the residue was purified using preparative HPLC.
  • Step 2 2M LiOH (aq.) (0.42 mL, 0.84 mmol) was added to a mixture of methyl 4-chloro-2- (cyclopent-1-en-1-yl)thiazole-5-carboxylate (195 mg, 0.80 mmol) in a 1:1:1 mixture of MeOH/THF/H 2 O (8 mL) and the mixture was stirred at rt for 20 h. The mixture was then concentrated and used in the next step without further purification.
  • Step 3 To a stirred solution of lithium 4-chloro-2-(cyclopent-1-en-1-yl)thiazole-5-carboxylate (190 mg, 0.81 mmol) in MeOH (8.064 m) was added NaBH 4 (153 mg, 4.03 mmol) in one portion at rt and the resulting solution was stirred at rt for 1 h. The reaction mixture was concentrated, the residue dissolved in CH 2 Cl 2 (20 mL) and treated with 1N HCl (10 mL). The aqueous phase was extracted with CH 2 Cl 2 and the combined organic phases were dried (MgSO 4 ) and concentrated to give an inseparable 2:1 mixture of cyclopentenyl and cyclopentyl compound.
  • Step 2 TFA (3 mL) was added to a solution of tert-butyl 2-(isoxazol-5-yl)-4-methylthiazole-5- carboxylate (300 mg, 1.126 mmol) in CH 2 Cl 2 (6 mL) and the soution was stirred at rt for 16 h. Then, the reaction mixture was concentrated to give 2-(isoxazol-5-yl)-4-methylthiazole-5- carboxylic acid (int-EC12).
  • Step 2 Pd(PPh 3 ) 4 (146 mg, 0.126 mmol) was added at rt to degassed mixture of (6- methoxypyridin-3-yl)boronic acid (427 mg, 2.65 mmol), 2M Na 2 CO 3 (4.4 mL, 8.8 mmol) and 2,4- dichlorothiazole-5-carboxylic acid (500 mg, 2.52 mmol) in DME (13 mL) and the mixture heated at 80 °C for 5 h. After cooling, the reaction mixture was treated with water and washed with ethyl acetate. The water phase was acidified with conc.
  • Step 1 Diphenyl phosphoryl azidate (DPPA) (9.0 mL, 40.7 mmol) and Et 3 N (4.2 mL, 30.0 mmol) were added to a solution of 3-(ethoxycarbonyl)-1-methyl-1H-pyrazole-5-carboxylic acid (5.0 g, 27.2 mmol) in tert-butanol (90 mL) and the reaction mixture stirred at 95 °C for 3 h. After cooling, the reaction mixture was concentrated and the residue was treated with water and ethyl acetate. The water phase was extracted with ethyl acetate.
  • DPPA diphenyl phosphoryl azidate
  • Step 2 1 M LiOH in H 2 O (25 mL, 24.14 mmol) was added to a suspension of methyl 5-((tert- butoxycarbonyl)amino)-1-methyl-1H-pyrazole-3-carboxylate (3.0 g, 11.75 mmol) in THF (45 mL) and the mixture was stirred at rt for 2 h. The THF was evaporated and the residue was treated with water and ethyl acetate. The water phase was acidified with conc.
  • Step 3 DPPA (0.95 mL, 4.29 mmol) and Et 3 N (0.44 mL, 3.15 mmol) were added to a solution 5-((tert-butoxycarbonyl)amino)-1-methyl-1H-pyrazole-3-carboxylic acid (690 mg, 2.86 mmol) in benzylacohol (9.0 mL) and the reaction mixture was stirred at 95 °C for 3 h. After cooling to rt, the reaction mixture was treated with water and ethyl acetate and the water phase was extracted with ethyl acetate.
  • Step 5 Pyridine (171 ⁇ l, 2.12 mmol) and EDC (162 mg, 0.848 mmol) were added at rt to a solution of tert-butyl (3-amino-1-methyl-1H-pyrazol-5-yl)carbamate (90 mg, 0.424 mmol) and isobutyric acid (44 ⁇ l, 0.466 mmol) in acetonitrile (4 mL).
  • Step 6 4M HCl in dioxane (1.24 mL, 4.96 mmol) was aded to a solution of tert-butyl (3- isobutyramido-1-methyl-1H-pyrazol-5-yl)carbamate (70 mg, 0.248 mmol) in CH 2 Cl 2 (2.5 mL) and the mixture was stirred at rt for 1 h. The reaction mixture was then concentrated and the oily residue was dissolved in CH 2 Cl 2 and concentrated, dissolved in Et 2 O and concentrated to give N-(5-amino-1-methyl-1H-pyrazol-3-yl)isobutyramide (int-EC38).
  • Step 2 4M HCl in dioxane (19 mL, 78 mmol) was added at rt to a solution of tert-butyl (4-chloro- 2-(isopropylcarbamoyl)thiazol-5-yl)carbamate (1.25 g, 3.91 mmol) in CH 2 Cl 2 (39 mL) and the solution stirred at rt for 16 h.
  • Step 2 4 M HCl in dioxane (1.3 mL, 5.2 mmol) was added at rt to a solution of tert-butyl (3-((2,2- difluoroethyl)carbamoyl)-1-methyl-1H-pyrazol-5-yl)carbamate (79 mg 0.26 mmol) in CH 2 Cl 2 (2.6 mmol) and the reaction mixture was stirred at rt for 2 h. The suspension was concentrated give 5-amino-N-(2,2-difluoroethyl)-1-methyl-1H-pyrazole-3-carboxamide (int-EC40).
  • Step 2 DPPA (1.10 mL, 5.02 mmol) and triethylamine (513 ⁇ l, 3.68 mmol) were added to a solution of 2-(ethoxycarbonyl)-4-methylthiazole-5-carboxylic acid (0.72 g, 3.35 mmol) in tert butanol (12 mL) and the reaction mixture stirred at 95 °C for 3 h. After cooling to rt, the solvent was removed, the residue was treated with water and extracted with ethyl acetate. The combined organic phases were washed with brine, dried (Na 2 SO 4 ) and concentrated.
  • Step 3 1M LiOH in H 2 O (10 mL, 10 mmol) was added to a suspension of ethyl 5-((tert- butoxycarbonyl)amino)-4-methylthiazole-2-carboxylate (0.60 g, 2.1 mmol) in THF (20 mL) and the mixture was stirred at rt for 7 h. The THF was then removed and the residue was treated with water and washed with ethyl acetate. The water phase was acidified with conc. HCl and the resulting white suspension was stirred for 30 min before being filtered off cold and dried under high vacuum to give 5-((tert-butoxycarbonyl)amino)-4- methylthiazole-2-carboxylic acid.
  • N-(5-amino-1-methyl-1H-pyrazol-3-yl)-2-fluorobenzamide (int-EC44) was obtained using an analogous method as that described for the synthesis of N-(5-amino-1-methyl-1H-pyrazol-3- yl)isobutyramide (int-EC38), except isobutyric acid (step 5) was replaced with 2-fluorobenzoic acid.
  • Step 2 Acetonitrile (0.687 mL, 13.16) was added at -78 °C to 1.6 M solution of n-BuLi in hexane (8.23 mL, 13.16 mmol) in THF (25 mL). After stirring the reaction mixture at -78 °C for 20 min., solution of methyl 3-cyclopropylisoxazole-5-carboxylate (1.1 g, 6.58 mmol) in THF (25 mL) was added dropwise at -78 °C. The reaction mixture was then stirred at -78 °C for 2 h before it was quenched by addition of 2N aq. HCl at -78 °C.
  • Step 3 A solution of 3-(3-cyclopropylisoxazol-5-yl)-3-oxopropanenitrile (1.2 g, 6.81 mmol) and methyl hydrazine (1.0 mL, 19.10 mmol) in EtOH (60 mL) was stirred at reflux for 16 h. After cooling to rt, the reaction mixture was concentrated and redissolved in EtOH. It was then evapoated to dryness.
  • methyl 6-(trifluoromethyl)nicotinate was obtained using the following procedure: 2M solution of trimethylsilyldiazomethane in hexane (32.7 mL, 65.4 mmol) was added at 0 °C to a solution of 6-(trifluoromethyl)nicotinic acid (5.0 g, 26.2 mmol) in MeOH (200 mL). After stirring the reaction mixture at 0 °C for 1 h, the reaction mixture was concentrated, treated with water and extracted with ethyl acetate. The combined organic layers were washed with sat. NaHCO 3 , dried (MgSO 4 ) and concentrated.
  • Step 1 A mixture of 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (578 mg, 2.78 mmol), Pd(PPh 3 ) 4 (146 mg, 0.126 mmol), 2M Na 2 CO 3 (4.4 mL, 8.8 mmol) and 2,4- dichlorothiazole-5-carboxylic acid (int-EC13, step 1, 500 mg, 2.52 mmol) in DME (13 mL) was heated to 80 °C for 5 h. After cooling to rt, the reaction mixture was treated with water and washed with ethyl acetate. The water phase was acidified with conc.
  • Step 2 DPPA (515 ⁇ L, 2.34 mmol) and triethylamine (261 ⁇ L, 1.87 mmol) were added at rt to a solution of 4-chloro-2-(1-methyl-1H-pyrazol-3-yl)thiazole-5-carboxylic acid (380 mg, 1.56 mmol) in tert-butanol (12 mL) and the reaction mixture was stirred at 95 °C for 3 h. After cooling to rt, the solvent was removed and the residue was treated with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na 2 SO 4 ) and concentrated.
  • Step 3 4M HCl in dioxane (7.6 mL, 30.5 mmol) was added at rt to a solution of tert-butyl (4- chloro-2-(1-methyl-1H-pyrazol-3-yl)thiazol-5-yl)carbamate (400 mg, 1.27 mmol) in CH 2 Cl 2 (25 mL). The reaction mixture was stirred at rt for 18 h before it was cooled to 0 °C. The solid was filtered off, washed with Et 2 O and dried in high vacuum to give 4-chloro-2-(1-methyl-1H-pyrazol- 3-yl)thiazol-5-amine (int-EC48).
  • N-(5-amino-1-methyl-1H-pyrazol-3-yl)-2,3-difluorobenzamide (int-EC50) was obtained using an analogous method as that described for the synthesis of N-(5-amino-1-methyl-1H-pyrazol-3- yl)isobutyramide (int-EC38), except isobutyric acid (step 5) was replaced with 2,3- difluorobenzoic acid.
  • Step 1 A solution of di-tert-butyl dicarbonate (2.237 mL, 9.63 mmol) in methanol (20 mL) was added dropwise at 0 °C to a mixture of 4-methyl-1,3-thiazol-5 amine (1.0 g, 8.76 mmol) and triethylamine (3.66 mL, 26.3 mmol) in methanol (50 mL) and the reaction mixture was stirred at rt for 16 h. After removal of the solvent was removed, the residue was dissolved in CH 2 Cl 2 and the solution was washed with water and sat. NaHCO 3 , dried (MgSO 4 ) and concentrated.
  • Step 2 Boc 2 O (3.74 g, 17.1 mmol) was added at rt to a mixture of 3-chloro-1H-pyrazol-4-amine (2.4 g, 15.6 mmol) and NaHCO 3 (2.88g, 34.3 mmol) in THF (28 mL)/H 2 O (2.8 mL) and the mixture was stirred at rt for 16 h. The mixture was then treated with water and ethyl acetate and the water phase was extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na 2 SO 4 ) and concentrated to give an oil.
  • Step 4 tert-Butyl (3-chloro-1-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-4-yl)carbamate (330 mg, 0.91 mmol) in CH 2 Cl 2 (0.91 mL) was treated with TFA (0.91 mL, 11.8 mmol) and the mixture was stirred at rt for 3 h. The reaction mixture was then diluted with CH 2 Cl 2 and treated with sat. NaHCO 3 .
  • N-(5-amino-1-methyl-1H-pyrazol-3-yl)pivalamide (int-EC60) was obtained using an analogous method as that described for the synthesis of N-(5-amino-1-methyl-1H-pyrazol-3- yl)isobutyramide (int-EC38), except isobutyric acid (step 5) was replaced with pivalic acid.
  • Step 2 A solution of 5-(3-methyl-4-nitro-1H-pyrazol-1-yl)-2-(trifluoromethyl)pyridine (1.12 g, 4.11 mmol) in ethanol (100 mL) was hydrogenated using H cube (10% Pd/C, 1 atm, 30 °C).
  • Example 1 N 2 ,4-dimethyl-N 5 -((R)-2-methyl-3-oxo-3-(((S)-11-oxo-2,3,10,11-tetrahydro-1H,5H- benzo[d]pyrazolo[1,2-a][1,2]diazepin-10-yl)amino)propyl)thiazole-2,5-dicarboxamide (1)
  • Step 1 To a solution of (S)-10-amino-2,3,5,10-tetrahydro-1H,11H-benzo[d]pyrazolo[1,2- a][1,2]diazepin-11-one (int-A1) (5.0 g, 11.12 mmol) in CH 3 CN (50 mL), were added (R)-3-((tert- butoxycarbonyl)amino)-2-methylpropanoic acid (int-L9) (2.26 g, 11.12 mmol), DIPEA (5.83 mL, 33.4 mmol) and TOTU (3.65 g, 11.12 mmol) and the reaction mixture was stirred at rt for 16 h.
  • int-A1 5.0 g, 11.12 mmol
  • DIPEA 5.
  • Step 2 tert-Butyl ((R)-2-methyl-3-oxo-3-(((S)-11-oxo-2,3,10,11-tetrahydro-1H,5H- benzo[d]pyrazolo[1,2-a][1,2]diazepin-10-yl)amino)propyl)carbamate (4.92 g, 11.0 mmol) was dissolved in 4N HCl (50 mL) and the reaction mixture was stirred at rt for 1 h. The reaction mixture was concentrated and then CH 3 CN/Et 2 O was added.
  • Step 3 4-Methyl-2-(methylcarbamoyl)thiazole-5-carboxylic acid (int-EC4) (10 mg, 0.04 mmol) and EDC (14.71 mg, 0.077 mmol) were added to a solution of (R)-3-amino-2-methyl-N-((S)-11- oxo-2,3,10,11-tetrahydro-1H,5H-benzo[d]pyrazolo[1,2-a][1,2]diazepin-10-yl)propanamide (13 mg, 0.038 mmol) in pyridine (2 mL) and the mixture was stirred at rt for 16 h.
  • int-EC4 4-Methyl-2-(methylcarbamoyl)thiazole-5-carboxylic acid
  • EDC 14.71 mg, 0.077 mmol
  • Example 2 N-((R)-2-(((S)-5,11-dioxo-2,3,10,11-tetrahydro-1H,5H-benzo[d]pyrazolo[1,2- a][1,2]diazepin-10-yl)carbamoyl)-3,3,3-trifluoropropyl)-4-methylisoxazole-5-carboxamide (2) Step 1.
  • the reaction mixture was concentrated, dissolved in ethyl acetate and washed with 1N HCl and with sat. NaHCO 3 solution, dried (MgSO 4 ) and concentrated to give a mixture of stereoisomers.
  • the crude was purified by flash chromatography (0-30% ethyl acetate in cyclohexane) to give the desired isomer tert-butyl ((R)-2-(((S)-5,11-dioxo-2,3,10,11-tetrahydro-1H,5H- benzo[d]pyrazolo[1,2-a][1,2]diazepin-10-yl)carbamoyl)-3,3,3-trifluoropropyl)carbamate.
  • Step 2 A mixture of tert-butyl ((R)-2-(((S)-5,11-dioxo-2,3,10,11-tetrahydro-1H,5H- benzo[d]pyrazolo[1,2-a][1,2]diazepin-10-yl)carbamoyl)-3,3,3-trifluoropropyl)carbamate (360 mg, 0.8 mmol) in 4M HCl in dioxane (10 mL, 40 mmol) was stirred at rt for 1 h. The reaction mixture was then concentrated and treated with CH 3 CN and Et 2 O.
  • Step 3.4-Methylisoxazole-5-carboxylic acid (int-EC29) (80 mg, 0.20 mmol) and EDC (75 mg, 0.39 mmol) were added at rt to a mixture of (R)-2-(aminomethyl)-N-((S)-5,11-dioxo-2,3,10,11- tetrahydro-1H,5H-benzo[d]pyrazolo[1,2-a][1,2]diazepin-10-yl)-3,3,3-trifluoropropanamide (50 mg, 0.39 mmol) in pyridine (2 mL) and the mixture was stirred at rt for 16 h.
  • Step 1 EDC (19.17 g, 100 mmol) was added to a solution of (R)-4-(tert-butoxy)-2-methyl-4- oxobutanoic acid (int-L6) (9.41 g, 50.0 mmol) and (S)-10-amino-2,3,5,10-tetrahydro-1H,11H- benzo[d]pyrazolo[1,2-a][1,2]diazepin-11-one (int-A1) (22.48 g, 50.0 mmol) in pyridine (300 mL) and the reaction mixture was stirred at rt for 18 h.
  • int-L6 a solution of (R)-4-(tert-butoxy)-2-methyl-4- oxobutanoic acid (int-L6) (9.41 g, 50.0 mmol) and (S)-10-amino-2,3,5,10-tetrahydro-1H,11H- benzo[d]pyrazolo[
  • Step 2 TFA (83 mL) was added to a solution of tert-butyl (R)-3-methyl-4-oxo-4-(((S)-11-oxo- 2,3,10,11-tetrahydro-1H,5H-benzo[d]pyrazolo[1,2-a][1,2]diazepin-10-yl)amino)butanoate (16.67 g, 43 mmol) in CH 2 Cl 2 (215 mL) and the mixture stirred at rt for 1 h. The reaction mixture was diluted with water, the organic layer was washed with water and the collected aqueous layers were extracted with CH 2 Cl 2 . The combined organic layers were dried (Na 2 SO 4 ) and concentrated.
  • Step 3 EDC (156 mg, 0.815 mmol) was added to a solution of (R)-3-methyl-4-oxo-4-(((S)-11- oxo-2,3,10,11-tetrahydro-1H,5H-benzo[d]pyrazolo[1,2-a][1,2]diazepin-10-yl)amino)butanoic acid (90 mg, 0.27 mmol), N-(5-amino-1-methyl-1H-pyrazol-3-yl)isobutyramide (int-EC38) (60 mg, 0.27 mmol) in pyridine (2.5 mL) and the mixture was stirred rt for 16 h.
  • Example 109 (R)-N 4 -(3-((2-fluorophenyl)carbamoyl)-1-methyl-1H-pyrazol-5-yl)-2-methyl-N 1 - ((S)-11-oxo-2,3,10,11-tetrahydro-1H,5H-benzo[d]pyrazolo[1,2-a][1,2]diazepin-10- yl)succinamide (109)
  • Step 1 EDC (1.15 g, (6.04 mmol) was added to a solution of (R)-3-methyl-4-oxo-4-(((S)-11-oxo- 2,3,10,11-tetrahydro-1H,5H-benzo[d]pyrazolo[1,2-a][1,2]diazepin-10-yl)amino)butanoic acid (see step 2 of Example 62), (1.0 g, 3.02 mmol), methyl 5-amino-1-methyl-1H-pyrazole
  • Step 2 1 M LiOH in H 2 O (15 mL, 15 mmol) was added to a mixture of methyl 1-methyl-5-((R)-3- methyl-4-oxo-4-(((S)-11-oxo-2,3,10,11-tetrahydro-1H,5H-benzo[d]pyrazolo[1,2-a][1,2]diazepin- 10-yl)amino)butanamido)-1H-pyrazole-3-carboxylate in THF (20 mL) and the mixture stirred at 0°C for 2 h.
  • Step 3 EDC (70 mg, 0.363 mmol) was added to a solution of 1-methyl-5-((R)-3-methyl-4-oxo-4- (((S)-11-oxo-2,3,10,11-tetrahydro-1H,5H-benzo[d]pyrazolo[1,2-a][1,2]diazepin-10- yl)amino)butanamido)-1H-pyrazole-3-carboxylic acid (55 mg, 0.121 mmol) and 2-fluoroaniline (int-EC77) (14 ⁇ l, 0.133 mmol) in pyridine (1.2 mL) and the mixture stirred at rt for 18 h. The reaction was treated with sat.
  • Example 3 shows additional example compounds (Example 107) which was prepared using a method analogous to that described in Example 109. The appropriate intermediates used in each step are listed, along with the coupling conditions for step 3.
  • Table 3 Example 111: (R)-3-(1H-benzo[d]imidazol-2-yl)-2-methyl-N-((S)-11-oxo-2,3,10,11-tetrahydro- 1H,5H-benzo[d]pyrazolo[1,2-a][1,2]diazepin-10-yl)propanamide (111) Step 1: To a solution of (R)-3-methyl-4-oxo-4-(((S)-11-oxo-2,3,10,11-tetrahydro-1H,5H- benzo[d]pyrazolo[1,2-a][1,2]diazepin-10-yl)amino)butanoic acid (see step 2 of Example 62) (20 mg, 0.060 mmol) in
  • reaction mixture was stirred for 30 min, until tert-butyl 2- aminophenylcarbamate (12.6 mg, 0.060 mmol) was added.
  • the reaction mixture was purified by preparative HPLC-MS (Waters, column X-Bridge C 18 ODB 5 ⁇ m 30*100 mm, flow 45 mL/min, water/ACN : 5->99% ACN in 12.5min, 7.3 mM NH 3 ) to give tert-butyl 2-((R)-3-methyl-4-oxo-4- ((S)-11-oxo-1,2,3,5,10,11-hexahydrobenzo[d]pyrazolo[1,2-a][1,2]diazepin-10- ylamino)butanamido)phenylcarbamate.
  • Step 2 Tert-butyl 2-((R)-3-methyl-4-oxo-4-((S)-11-oxo-1,2,3,5,10,11- hexahydrobenzo[d]pyrazolo[1,2-a][1,2]diazepin-10-ylamino)butanamido)phenylcarbamate (101 mg, 0.19 mmol) was dissolved in a 1.25 M HCl solution in MeOH (3 mL, 3.8 mmol). The sample was heated to 150°C for 30 min in a microwave. The reaction mixture was concentrated under vacuum and coevaporated three times with a 7N NH 3 solution in MeOH.
  • reaction mixture was purified by preparative HPLC-MS (column X-Bridge C 18 ODB 5 um 30*100 mm, flow 45 mL/min, water/ACN : 5->99% ACN in 12.5 min, 7.3 mM NH 3 ) to give (R)-3-(1H- benzo[d]imidazol-2-yl)-2-methyl-N-((S)-11-oxo-2,3,10,11-tetrahydro-1H,5H- benzo[d]pyrazolo[1,2-a][1,2]diazepin-10-yl)propanamide (111).
  • Table 4 shows additional example compounds (Examples 112 to 119) which were prepared using a method analogous to that described in Example 111. The appropriate intermediates used in each step are listed, along with the coupling conditions for step 4.
  • the assay is based on the coupling of the proteolytic degradation of a membrane bound synthetic substrate (VP16-Gal4 fusion protein with the N-terminal domain of TNF alpha), which migrates to the nucleus upon cleavage, with the Gal4 driven expression of luciferase.
  • a membrane bound synthetic substrate VP16-Gal4 fusion protein with the N-terminal domain of TNF alpha
  • Inhibition of Sppl2a results in a reduction of nuclear VP16-Gal4 activator and therefore in a reduction of the production of luciferase.
  • the luciferase dependent-luminescence is plotted against the concentrations of compound to generate a dose response curve, which allows the calculation of the IC 50 value.
  • DNA vectors encoding human Sppl2a, NT-TNF-VP16-Gal4 and a Gal4-luciferase reporter were transiently transfected in HEK293 cells.
  • 5 ⁇ g plasmid for SPPL2a 10 ⁇ g plasmid encoding the reporter Gal4-luciferase and 20 ⁇ g plasmid encoding the substrate NT-TF- VP16-Gal4 were mixed together.
  • the DNA mixture was combined with 107 ⁇ l FuGENE® (Promega), 735 ⁇ l Opti-MEM® (Life Technologies) and incubated for 5 minutes at RT. To this mixture 20 mL of concentrated HEK293 cells were added and thoroughly mixed.
  • the cell suspension was distributed to a white solid 384 well plate. Within 5 hours, 50 nl of compound in DMSO was stamped into the wells via pintool. The plate was incubated for 24h at 37 o C, 5% CO 2 in a humidified incubator, before the addition of 25 ⁇ l Bright Glo. After incubation at RT for 5 min, the plate was transferred to a luminometer and the luminescence was measured. The IC 50 was determined by plotting compound concentration vs. normalized luminescence values.
  • ⁇ -secretase RGA reporter gene assay: Presenilins are the active subunits of ⁇ -secretase complex; a membrane bound protease that cleaves numerous type I transmembrane substrates.
  • the current assay has been developed to monitor the ⁇ -secretase activity toward Notch, an important modulator of immune cells development.
  • the assay is based on the coupling of the proteolytic degradation of a membrane bound synthetic substrate, a VP16-Gal4 fusion protein with Notch1, which migrates to the nucleus upon cleavage, where it activates Gal4 driven expression of luciferase.
  • Inhibitors of ⁇ - secretase will result in a reduction of nuclear VP16-Gal4 activator and therefore in a reduction of the production of luciferase.
  • the luciferase dependent-luminescence is plotted against the concentrations of compound to generate a dose response curve, which allows the calculation of the IC 50 value.
  • DNA vectors encoding human Notch1-VP16-Gal4 and a Gal4-luciferase reporter were transiently transfected in HEK293 cells, which express ⁇ -secretase components endogenously.
  • 10 ⁇ g plasmid encoding the reporter Gal4-luciferase and 20 ⁇ g plasmid encoding the substrate Notch1-VP16-Gal4 were mixed together.
  • the DNA mixture was combined with 107 ⁇ l FuGENE® (Promega), 735 ⁇ l Opti-MEM® (Life Technologies) and incubated for 5 minutes at RT. To this mixture 20 mL of concentrated HEK293 cells were added and thoroughly mixed. The cell suspension was distributed to a white solid 384 well plate.
  • Stable U-2 OS cell lines expressing human SPPL2a constitutively and a EGFP-labeled TNF ⁇ (aa1-76) NTF substrate under a doxycycline-regulated promoter were used for the imaging assays.
  • Cells were seeded at 3000 cells/30 ⁇ L/384-well in DMEM/GlutaMaxTM-I (Invitrogen) supplemented with tetracycline-free 10% FBS (Amimed) and incubated at 37 °C, 5% CO 2 for 3 ⁇ 4 h.
  • the plates were imaged using a Cellomics ArrayScan VTI HCS reader with 10 ⁇ / 0.3NA objective (Thermo Fisher Scientific, USA). Six images per well were acquired. Images for the EGFP signal (Ex395, Em509) and the Hoechst nuclear dye (Ex350, Em425) were acquired simultaneously with image analysis using the “Nuclear Translocation” assay algorithm of the Cellomics ArrayScan software. Nuclei were detected based on the Hoechst staining, the nuclear mask was transferred to the EGFP channel, and a 4 pixel wide cytoplasm ring region was defined around the nucleus.
  • the IC 50 value was calculated from the plot of percentage of inhibition vs inhibitor concentration using nonlinear regression analysis software, e.g., Origin (OriginLab Corp.).
  • CD74/p8 mouse whole blood assay flow cytometry format Mouse whole blood Balb/c mice (sodium citrate) was ordered by Bioreclamation LLC; USA. The blood was used the next day upon receipt (stored at 4 °C).100 ⁇ L blood were transferred in 96 well format plate, where compounds, an 11 point dilutions down from 30 ⁇ M, to be tested were previously deposited. The plate was incubated for 5 h in the incubator at 37 °C, 5% CO 2 under continuous motion.
  • RBC Lysis Buffer (Amined; Cat. Nr 3-13F00-H or BD; Cat. Nr 555899). The solution was mixed by pipetting and incubated 10 min in the 37 °C incubator. The white blood cells were sedimented for 3 min at 2000 rpm. After removing the supernatant the cell pellet was resuspended and washed twice in RCB Buffer and kept ⁇ 5 min at room temperature, followed by a centrifugation for 2 min at 2000 rpm. The cell pellet was then resuspend in D-PBS and centrifuged twice. Finally, the cells were taken up in of D-PBS/0.5% inactivated fetal bovine serum/2mM EDTA.
  • the cell suspension was treated with Live/Dead fixable stain (Life Technologies, >470 nm version), B cells were identified by surface staining with an anti-B220 antibody coupled to APC fluorofor. After staining, the cells were extensively washed with PBS. The cells were permeabilized and fixed in FACS lysing buffer; (BD; # 349202 ⁇ dil 1:10 in water) and labelled with an anti CD74, FITC labelled antibody, washed once more with diluted FACS lysing buffer and spin down. The cell pellet was washed with D-PBS/0.5% inactivated fetal bovine serum/2 mM EDTA and PBS prior to the analysis in a flow cytometer.
  • Live/Dead fixable stain Life Technologies, >470 nm version

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/IB2021/058398 2020-09-17 2021-09-15 Compounds and compositions as sppl2a inhibitors Ceased WO2022058902A1 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
RS20250568A RS66874B1 (sr) 2020-09-17 2021-09-15 Jedinjenja i kompozicije kao inhibitori sppl2a
AU2021342783A AU2021342783A1 (en) 2020-09-17 2021-09-15 Compounds and compositions as sppl2a inhibitors
EP21773886.3A EP4214210B1 (en) 2020-09-17 2021-09-15 Compounds and compositions as sppl2a inhibitors
JP2023517751A JP7771172B2 (ja) 2020-09-17 2021-09-15 Ｓｐｐｌ２ａ阻害剤としての化合物及び組成物
SI202130298T SI4214210T1 (sl) 2020-09-17 2021-09-15 Spojine in sestavki kot zaviralci sppl2a
LTEPPCT/IB2021/058398T LT4214210T (lt) 2020-09-17 2021-09-15 Junginiai ir kompozicijos kaip sppl2a inhibitoriai
CR20230142A CR20230142A (es) 2020-09-17 2021-09-15 Compuestos y composiciones como inhibidores de sppl2a
MX2023003122A MX2023003122A (es) 2020-09-17 2021-09-15 Compuestos y composiciones como inhibidores de la péptido señal peptidasa similar a la proteasa 2a (sppl2a).
MA61557A MA61557B1 (fr) 2020-09-17 2021-09-15 Composés et compositions servant d'inhibiteurs de sppl2a
US18/044,455 US20230365571A1 (en) 2020-09-17 2021-09-15 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS
CN202180074962.XA CN116615425B (zh) 2020-09-17 2021-09-15 作为Sppl2a抑制剂的化合物和组合物
SM20250216T SMT202500216T1 (it) 2020-09-17 2021-09-15 Composti e composizioni come inibitori di sppl2a
PL21773886.3T PL4214210T3 (pl) 2020-09-17 2021-09-15 Związki i kompozycje jako inhibitory sppl2a
CA3192763A CA3192763A1 (en) 2020-09-17 2021-09-15 Compounds and compositions as sppl2a inhibitors
PE2023001167A PE20231099A1 (es) 2020-09-17 2021-09-15 COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE Sppl2a
FIEP21773886.3T FI4214210T3 (fi) 2020-09-17 2021-09-15 Yhdisteitä ja koostumuksia sppl2a:n estäjinä
DK21773886.3T DK4214210T3 (da) 2020-09-17 2021-09-15 Forbindelser og sammensætninger som sppl2a-inhibitorer
HRP20250562TT HRP20250562T1 (hr) 2020-09-17 2021-09-15 Spojevi i pripravci kao inhibitori sppl2a
IL300953A IL300953B1 (en) 2020-09-17 2021-09-15 Compounds and preparations as SPPL2A inhibitors
MDE20230725T MD4214210T2 (ro) 2020-09-17 2021-09-15 Compuși și compoziții ca inhibitori SPPL2A
EP25163259.2A EP4578451A3 (en) 2020-09-17 2021-09-15 Compounds and compositions as sppl2a inhibitors
KR1020237011546A KR20230069947A (ko) 2020-09-17 2021-09-15 Sppl2a 억제제로서의 화합물 및 조성물
ES21773886T ES3028668T3 (en) 2020-09-17 2021-09-15 Compounds and compositions as sppl2a inhibitors
JOJO/P/2023/0044A JOP20230044A1 (ar) 2020-09-17 2023-02-27 مركبات وتركيبات كمثبطات sspl2a
DO2023000055A DOP2023000055A (es) 2020-09-17 2023-03-16 COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE Sppl2a
CONC2023/0004646A CO2023004646A2 (es) 2020-09-17 2023-04-14 Compuestos y composiciones como inhibidores de sppl2a
JP2025186205A JP2026041723A (ja) 2020-09-17 2025-11-05 Ｓｐｐｌ２ａ阻害剤としての化合物及び組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063079604P 2020-09-17 2020-09-17
US63/079,604 2020-09-17

Publications (1)

Publication Number Publication Date
WO2022058902A1 true WO2022058902A1 (en) 2022-03-24

Family

ID=77897680

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/058398 Ceased WO2022058902A1 (en) 2020-09-17 2021-09-15 Compounds and compositions as sppl2a inhibitors

Country Status (30)

Country Link
US (1) US20230365571A1 (https=)
EP (2) EP4578451A3 (https=)
JP (2) JP7771172B2 (https=)
KR (1) KR20230069947A (https=)
AU (1) AU2021342783A1 (https=)
CA (1) CA3192763A1 (https=)
CL (2) CL2023000728A1 (https=)
CO (1) CO2023004646A2 (https=)
CR (1) CR20230142A (https=)
DK (1) DK4214210T3 (https=)
DO (1) DOP2023000055A (https=)
EC (1) ECSP23027092A (https=)
ES (1) ES3028668T3 (https=)
FI (1) FI4214210T3 (https=)
GE (2) GEAP202516217A (https=)
HR (1) HRP20250562T1 (https=)
HU (1) HUE071569T2 (https=)
IL (1) IL300953B1 (https=)
JO (1) JOP20230044A1 (https=)
LT (1) LT4214210T (https=)
MA (1) MA61557B1 (https=)
MD (1) MD4214210T2 (https=)
MX (1) MX2023003122A (https=)
PE (1) PE20231099A1 (https=)
PL (1) PL4214210T3 (https=)
PT (1) PT4214210T (https=)
RS (1) RS66874B1 (https=)
SI (1) SI4214210T1 (https=)
SM (1) SMT202500216T1 (https=)
WO (1) WO2022058902A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116947813A (zh) * 2023-07-06 2023-10-27 绍兴贝斯美化工股份有限公司 一种3-氯-4-氨基-1-(3-吡啶基)-1h-吡唑的制备方法
WO2025175102A1 (en) 2024-02-15 2025-08-21 Incyte Corporation Sppl2a inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048998A (en) 1996-06-17 2000-04-11 Zeneca Limited One-step process for preparing methyl 2-(halomethyl)phenylacetate from 3-isochromanone
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2015160772A1 (en) 2014-04-15 2015-10-22 Janssen Pharmaceutica Nv Tetrahydro-benzoimidazolyl modulators of tgr5

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2124503C1 (ru) * 1992-05-18 1999-01-10 И.Р.Сквибб энд Санз, Инк. Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
EP1773348A4 (en) 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc TETRA PEPTIDE ANALOGS
JP2008545780A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 有機化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048998A (en) 1996-06-17 2000-04-11 Zeneca Limited One-step process for preparing methyl 2-(halomethyl)phenylacetate from 3-isochromanone
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2015160772A1 (en) 2014-04-15 2015-10-22 Janssen Pharmaceutica Nv Tetrahydro-benzoimidazolyl modulators of tgr5

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1990, MACK PRINTING COMPANY, pages: 1289 - 1329
A. EL-FAHAMF. ALBERICIO, CHEM. REV., vol. 111, 2011, pages 6557 - 6602
A. G. SCHULTZT. J. GUZIE. LARSSONR. RAHMK. THAKKARJ. M. BIDLACK, J. ORG. CHEM., vol. 63, 1998, pages 7795 - 7804
C. V. C. PRASAD ET AL., BIOORG. MED. CHEM., vol. 17, 2007, pages 4006 - 4011
D. A. EVANSL. D. WUJ. J. M. WIENERJ. S. JOHNSOND. H. B. RIPINJ. S. TEDROW, J. ORG. CHEM., vol. 64, 1999, pages 6411 - 6417
D. BEISNER ET AL.: "The intramembrane protease Sppl2a is required for B cell and DC development and survival via cleavage of the invariant chain", J. EXP. MED., vol. 210, 2013, pages 23 - 39
E. E. BOROSF. BOUVIERS. RANDHAWAM. H. RABINOWITZ, J. HETEROCYCL. CHEM., vol. 38, 2001, pages 613 - 616
E. VALEURM. BRADLEY, CHEM. SOC. REV., vol. 38, 2009, pages 606 - 631
F. HOFFMANN-EMERYR. JAKOB-ROETNEA. FLOHRF. BLISSR. REENTS, TET. LETT., vol. 50, 2009, pages 6380 - 6382
J. F. W. MCOMIE: "Protective Groups in Organic Chemistry", 1973, PLENUM PRESS
J. M. KEITHJ. F. LARROWE. N. JACOBSEN, ADV. SYNTH. CATAL., vol. 343, 2001, pages 5 - 26
P. M. DONATED. FREDERICOR. DASILVAM. G. CONSTANTINOG. DEL PONTEP. S. BONATTO, TETRAHEDRON:ASYMMETRY, vol. 14, 2003, pages 3253 - 3256
S.-E. SUHS.-J. CHENM. MANDALI. A. GUZEIC. J. CRAMERS. S. STAHL, J. AM. CHEM. SOC., vol. 142, 2020, pages 11388 - 11393
THOMPSON ET AL.: "Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors", BIOORG. MED. CHEM. LETT., vol. 16, no. 9, 1 May 2006 (2006-05-01), pages 2357 - 2363, XP027966232, ISSN: 0960-894X, [retrieved on 20060501] *
VELCICKY ET AL.: "Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In Vivo", J. MED. CHEM., vol. 61, no. 3, 23 January 2018 (2018-01-23), US, pages 865 - 880, XP055848762, ISSN: 0022-2623, Retrieved from the Internet <URL:http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b01371> DOI: 10.1021/acs.jmedchem.7b01371 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116947813A (zh) * 2023-07-06 2023-10-27 绍兴贝斯美化工股份有限公司 一种3-氯-4-氨基-1-(3-吡啶基)-1h-吡唑的制备方法
WO2025175102A1 (en) 2024-02-15 2025-08-21 Incyte Corporation Sppl2a inhibitors

Also Published As

Publication number Publication date
DOP2023000055A (es) 2023-06-15
CO2023004646A2 (es) 2023-07-21
SI4214210T1 (sl) 2025-07-31
JP2023541475A (ja) 2023-10-02
MD4214210T2 (ro) 2025-10-31
HUE071569T2 (hu) 2025-09-28
EP4578451A3 (en) 2025-09-17
AU2021342783A9 (en) 2024-09-12
EP4578451A2 (en) 2025-07-02
KR20230069947A (ko) 2023-05-19
MX2023003122A (es) 2023-03-22
CN116615425A (zh) 2023-08-18
PT4214210T (pt) 2025-05-22
IL300953A (en) 2023-04-01
AU2021342783A1 (en) 2023-05-18
IL300953B1 (en) 2026-04-01
PL4214210T3 (pl) 2025-08-18
ECSP23027092A (es) 2023-06-30
JP2026041723A (ja) 2026-03-10
JOP20230044A1 (ar) 2023-02-27
CL2023000728A1 (es) 2023-12-15
CR20230142A (es) 2023-08-25
CA3192763A1 (en) 2022-03-24
EP4214210B1 (en) 2025-04-09
MA61557B1 (fr) 2025-05-30
SMT202500216T1 (it) 2025-07-22
HRP20250562T1 (hr) 2025-07-04
ES3028668T3 (en) 2025-06-19
GEAP202516217A (en) 2025-02-10
LT4214210T (lt) 2025-07-25
GEP20257771B (en) 2025-06-10
DK4214210T3 (da) 2025-06-10
RS66874B1 (sr) 2025-06-30
EP4214210A1 (en) 2023-07-26
JP7771172B2 (ja) 2025-11-17
PE20231099A1 (es) 2023-07-18
US20230365571A1 (en) 2023-11-16
CL2024001312A1 (es) 2024-10-11
FI4214210T3 (fi) 2025-05-26

Similar Documents

Publication Publication Date Title
CN105940002B (zh) ROR-γ的二氢吡咯并吡啶抑制剂
KR20210086674A (ko) Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물
JP2026041723A (ja) Ｓｐｐｌ２ａ阻害剤としての化合物及び組成物
CN111164069A (zh) 作为atf4抑制剂用于治疗癌症和其它疾病的n-(3-(2-(4-氯苯氧基)乙酰胺基)双环[1.1.1]戊-1-基)-2-环丁烷-1-甲酰胺衍生物以及相关化合物
KR20150128891A (ko) 인돌아민 2,3-디옥시게나제 (ido)의 억제제
TW201706274A (zh) 吡咯［２，３－ｄ］嘧啶基、吡咯［２，３－ｂ］吡基和吡咯［２，３－ｂ］吡啶基丙烯醯胺及其環氧化物
CN107074805A (zh) 用于治疗疾病的gls1抑制剂
CA2980161A1 (en) Heterocyclic compounds useful as inhibitors of tnf
JP2021528405A (ja) ＲＯＲγｔのモジュレータとしてのアミド置換チアゾール
WO2021117759A1 (ja) 含窒素芳香族複素環式基を有するヒストン脱アセチル化酵素阻害剤
CN116615425B (zh) 作为Sppl2a抑制剂的化合物和组合物
HK40128790A (en) Compounds and compositions as sppl2a inhibitors
EA031310B1 (ru) Производные пиперидина и азепина как модуляторы рецептора прокинетицина
US20250263416A1 (en) SPPL2a INHIBITORS
EP3759085B1 (en) Substituted cyclohexyl compounds as nop inhibitors
EA048012B1 (ru) Соединения и композиции в качестве ингибиторов sppl2a
US7816378B2 (en) Cyclic ketal beta-secretase inhibitors for the treatment of alzheimer&#39;s disease
WO2025133915A1 (en) Compounds which bind to pnpla3i148m and their use to treat liver diseases
US20220331304A1 (en) Compounds for use in treating neurological disorders
JP2025541737A (ja) Ｍａｓｐ－２阻害物質としての縮合ピリミジン
HK40130359A (zh) 犬janus激酶抑制剂及其用途
HK40070643A (en) Thiazole carboxamide compounds and use thereof for the treatment of mycobacterial infections
HK40034295A (en) Substituted cyclohexyl compounds as nop inhibitors
HK40034295B (en) Substituted cyclohexyl compounds as nop inhibitors
HK40008443A (en) Imidazopyrrolopyridine as inhibitors of the jak family of kinases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21773886

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3192763

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 300953

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: DZP2023000245

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 2023517751

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202317018760

Country of ref document: IN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023004963

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20237011546

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 16217

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: NC2023/0004646

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021773886

Country of ref document: EP

Effective date: 20230417

WWE Wipo information: entry into national phase

Ref document number: 202180074962.X

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2021342783

Country of ref document: AU

Date of ref document: 20210915

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112023004963

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230316

WWP Wipo information: published in national office

Ref document number: NC2023/0004646

Country of ref document: CO

WWG Wipo information: grant in national office

Ref document number: 2021773886

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: P-2025/0568

Country of ref document: RS

WWG Wipo information: grant in national office

Ref document number: P-2025/0568

Country of ref document: RS

WWD Wipo information: divisional of initial pct application

Ref document number: 327099

Country of ref document: IL